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1 Abstract 
 
Diabetic microangiopathy, a hyperglycaemia-induced damage of blood capillaries of long-
term diabetic patients is characterized by thickening of the capillary basement membrane. 
Diabetic microvascular complications generally affect the eyes (retinopathy), kidneys 
(nephropathy) and nerves (neuropathy). A gene set consisting of 125 genes, identified by gene 
expression profiling comparing (i) blood vascular endothelial cells (BECs) derived from 
tissue samples of diabetic and non-diabetic patients and (ii) BECs cultured in vitro under 
diabetic conditions, as well as by literature search was hypothesized to control these 
complications. The 125 candidate genes were the basis of a gene network that was assumed to 
be of functional relevance for diabetic microangiopathy by demonstration of the functional 
links between the genes involved. One of the identified candidate genes was HOXA3, a 
member of the family of homeobox genes encoding homeodomain transcription factors. 
Quantitative real time PCR of cDNA samples derived from total RNA of immortalized human 
umbilical vein endothelial cells (iHUVECs) transiently transfected with pIRES2-EGFP 
carrying the coding sequence of HOXA3 was executed, in order to study the effects of 
HOXA3 overexpression on the candidate gene set. Thereby, transient expression of HOXA3 
was found to result in elevated expression of genes encoding proteins that act in adipocytes or 
are involved in reorganization of the actin cytoskeleton. In a final gene network comprising 
37 genes and relevant to diabetic microangiopathy, expression of HOXA3 was positively 
regulated by CFL1 encoding cofilin 1 and downregulated by CASP3 coding for caspase 3. 
CFL1 a member of the family of actin depolymerising factor (ADF)/cofilins is known to 
contribute to cytoskeletal dynamics in nonmuscle cells whereas CASP3 encodes an effector 
caspase that mediates apoptosis of β-cells of the pancreas. Furthermore, it was found that 
HOXA3 may also have an activating effect on its own expression.  
The number of functional links to other genes involved determined the position of a gene 
within our network. Genes occupying a central position were thought to be key players in the 
occurrence of microvascular complications since they had a higher number of functional links 
than genes placed in a peripheral position. In our gene network assumed to be of relevance for 
diabetic microangiopathy, HOXA3 occupied a peripheral position. 
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2 Zusammenfassung 
 
Unter diabetischer Mikroangiopathie versteht man den durch Hyperglykämie verursachten 
Schaden an Blutkapillaren von Patienten, die über einen längeren Zeitraum unter erhöhtem 
Blutglukosespiegel stehen. Eine Verdickung der kapillären Basalmembran ist charakteristisch 
für das Auftreten dieser mikrovaskulären Komplikationen, die im Allgemeinen in den 
Kapillaren der Augen (Retinopathie) und der Nieren (Nephropathie) sowie in den Nerven 
(Neuropathie) zu finden sind. Basierend auf sowohl vergleichender Analyse der 
Genexpression in Blutgefäßendothelzellen (BECs) von Diabetikern und gesunden Menschen, 
sowie in BECs, die in vitro unter diabetischen Bedingungen kultiviert wurden, sowie durch 
Literatursuche konnten 125 Kandidatengene identifiziert werden, von denen man annahm, das 
Auftreten diabetischer Mikroangiopathie zu kontrollieren. Diese 125 Gene sollten die 
Grundlage für ein Gennetzwerk bilden, mit dessen Hilfe die genregulatorischen Interaktionen 
dargestellt werden konnten, welche für das Eintreten von diabetischen mikrovaskulären 
Komplikationen verantwortlich sind. Unter den identifizierten Kandidatengenen befand sich 
HOXA3, ein Mitglied der Familie von Homöoboxgenen, die für Transkriptionsfaktoren mit 
einer Homöodomäne kodieren. Um die Auswirkung der Überexpression des HOXA3 Gens 
auf die Expression der Kandidatengene zu untersuchen, wurden immortalisierte BECs einer 
humanen Nabelschnurvene (iHUVECs) transient mit dem Expressionsvektor pIRES2-EGFP, 
der die kodierende Sequenz von HOXA3 enthielt, transfiziert. Nach Isolation der gesamten 
RNA und reverser Transkription, wurde die resultierende cDNA Probe einer quantitativen 
real time PCR unterzogen. Durch die quantitative real time PCR konnte gezeigt werden, dass 
infolge einer Überexpression des HOXA3-Gens die Expression solcher Gene stark erhöht 
wurde, welche entweder in Adipozyten aktiv sind oder eine Rolle bei der Reorganisation des 
Aktinzytoskeletts spielen. 
In dem von uns gestalteten, 37 Gene umfassenden Netzwerk, wurde die Expression von 
HOXA3 zum einen durch CFL1 positiv reguliert und zum anderen durch CASP3 inhibiert. 
CFL1 kodiert für Cofilin 1, ein Aktin bindendes Protein, das zur zytoskelettalen Dynamik in 
Nicht-Muskelzellen beiträgt, während das Genprodukt von CASP3, eine Effektorkaspase, den 
programmierten Zelltod von β-Zellen des Pankreas herbeiführt.  
Die Position eines jeden Gens innerhalb des Netzwerks wurde durch die Zahl seiner direkten 
funktionellen Verknüpfungen mit anderen Genen bestimmt. Dabei waren jene Gene mit den 
meisten direkten funktionellen Verknüpfungen im Zentrum angeordnet, und ihnen wurde 
deshalb auch eine zentrale Rolle bei der Entstehung von diabetischen mikrovaskulären 
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Komplikationen beigemessen. Das HOXA3 Gen besetzte gemäß der Anzahl seiner direkten 
funktionellen Verknüpfungen eine periphere Position innerhalb des 37 Gene umfassenden 
Netzwerks.  
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3 Introduction 
 
3.1 Diabetes mellitus and diabetic microangiopathy 
 
3.1.1 Diabetes mellitus 
 
Diabetes mellitus is a metabolic disorder existing in different forms, all of which are 
characterized by hyperglycaemia. In fact, diabetes mellitus is diagnosed in patients with 
fasting plasma glucose levels above 126 mg/dl (7.0mmol/l) or casual plasma glucose levels 
above 200mg/dl (11.1mmol/l).  
Mechanisms contributing to the occurrence of hyperglycaemia are known to be failures in 
either action or secretion or both of the glucose-lowering pancreatic hormone insulin. A 
permanent state of hyperglycaemia causes various dysfunctions and defects of organs 
including the eyes (retinopathy), kidneys (nephropathy), nerves (neuropathy) and heart 
(cardiomyopathy). Clinical symptoms associated with the occurrence of hyperglycaemia are 
known to be polyuria, polydipsia and weight loss. In some cases, polyphagia, impaired vision 
and susceptibility to certain infections may be indicators of hyperglycaemia.  
Patients suffering from diabetes mellitus bear an increased risk for atherosclerotic 
cardiovascular, peripheral arterial and cerebrovascular disease. 
Several forms of diabetes mellitus are known, the three major types are type 1 diabetes, type 2 
diabetes and gestational diabetes.  
Type 1 diabetes, also referred to as insulin-dependent diabetes or juvenile-onset diabetes, is 
an autoimmune disease and occurs as the result of absolute insulin deficiency due to 
autoimmune destruction of insulin-producing pancreatic β-cells. Although type 1 diabetes can 
appear at any age, persons usually affected are children and adolescents. People with this 
form of diabetes require insulin for survival and therefore have to take insulin by injection up 
to several times a day. Type 1 diabetes accounts for 5-10 % of all patients suffering from 
diabetes. Markers identified for the autoimmune destruction of the β-cells of the pancreas are 
several autoantibodies targeted to islet cells, to insulin, to glutamic acid decarboxylase 
(GAD65) and to tyrosine phosphatases IA-2 and IA-2β. Diabetic ketoacidosis (DKA), defined 
as a state characterized by hyperglycaemia, accumulated ketone bodies in the blood as well as 
increased acidity of the blood, is a life-threatening condition that can occur as a result of 
insulin deficiency. Diabetic ketoacidosis is commonly found in people with type 1 diabetes, 
although it can also happen to patients suffering from type 2 diabetes. Although the causes of 
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type 1 diabetes are widely unknown, it is believed that genetic predispositions and 
environmental factors may play a decisive role in the development of the disease. Another 
rare form of type 1 diabetes, referred to as idiopathic diabetes, is commonly found in people 
of African or Asian descent. In contrast to autoimmune mediated type 1 diabetes described 
above, this form is not characterized by autoimmune destruction of the β-cells of the pancreas, 
but rather by a lack of ß-cell autoimmunity markers. 
The most prevalent form of diabetes is type 2 diabetes that accounts for 90-95% of all 
diabetes cases. Type 2 diabetes is also referred to as non-insulin dependent diabetes or adult-
onset diabetes and occurs as the result of insulin resistance and relative insulin deficiency. In 
contrast to type 1 diabetes, there is no autoimmune destruction of pancreatic β-cells found in 
patients with type 2 diabetes. In many cases, type 2 diabetes remains unnoticed for years due 
to a gradual emergence of hyperglycaemia. Risk factors identified for type 2 diabetes include 
obesity, low physical activity and advanced age. Furthermore, the occurrence of type 2 
diabetes is often linked to genetic predisposition. Unlike people suffering from type 1 
diabetes, patients with type 2 diabetes often do not depend on insulin treatment for survival. 
Glucose intolerance that arises or is first noticed during pregnancy is also known as 
gestational diabetes mellitus (GDM). Several factors including obesity, a family history of 
diabetes, abnormal glucose metabolism before pregnancy and being a member of an ethnic 
group with a high incidence of diabetes are known to increase the risk for women of 
developing this form of diabetes. In the majority of cases, women affected by GDM are older 
than 25 years indicating the influence of age on the development of GDM (American 
Diabetes Association, 2007). 
On the long term the result of all types of diabetes may be macrovascular and microvascular 
complications. In this thesis, only microangiopathic damage is dealt with. 
 
3.1.2 Diabetic microangiopathy 
 
Diabetic microangiopathy is a glucose-induced damage of blood capillaries of long-term 
diabetic patients. It is characterized by thickening of the capillary basement membrane. These 
diabetic microvascular complications are found in the eye (retinopathy) and in the kidney 
(nephropathy), and they are also involved in neuropathy. Besides direct damage to 
parenchymal cells, capillary damage is the most important mediator of organ dysfunction. 
Hyperglycaemia considered as the primary initiating factor for all types of diabetic 
microvascular disease seems to be responsible for several mechanisms characteristic for the 
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occurrence of diabetic microangiopathy. These mechanisms include structural, functional and 
biochemical changes. Structural changes in the form of thickening of the capillary basement 
membrane can result in occlusive angiopathy, tissue hypoxia and damage. Functional changes 
include increases in organ blood flow and vascular permeability, as well as abnormalities in 
blood viscosity, platelet and endothelial function (K Dahl-Jørgensen, 1998). Finally, four 
biochemical mechanisms are known to contribute to microvascular complications in diabetes, 
all of them induced by hyperglycaemia (Brownlee, 2001; Schalkwijk and Stehouwer, 2005).  
 Increased polyol pathway flux is one biochemical mechanism typical for the occurrence of 
diabetic vascular diseases. In the beginning of this pathway, the enzyme aldose reductase 
catalyzes the NADPH-dependent reduction of glucose to sorbitol. Under non-diabetic 
conditions, metabolism of glucose by the polyol pathway occurs at very low rates due to a 
low affinity of the enzyme aldose reductase for glucose. However, hyperglycaemia leads to 
increased conversion of intracellular glucose to sorbitol accompanied by an increase in 
oxidation of NADPH to NADP+. Another enzyme of the polyol pathway, sorbitol 
dehydrogenase catalyzes the oxidation of sorbitol to fructose with simultaneous reduction of 
NAD+ to NADH. Although there are many hypotheses about the damaging effects the 
products of the polyol pathway may have on cells, the role of this pathway in diabetic 
microvascular complications is not completely understood yet (Brownlee, 2001). The most 
plausible mechanism by which increased polyol pathway flux damages cells is based on the 
assumption that NADPH-dependent reduction of glucose to sorbitol depletes NADPH which 
in turn is essential for regeneration of reduced glutathione (GSH). The consequence of this 
NADPH consumption is oxidative stress (Lee and Chung, 1999). 
Another biochemical mechanism induced by hyperglycaemia and critical for microvascular 
complications in diabetes is the increased intracellular formation of advanced glycation 
end products (AGEs). Non-enzymatic glycation of proteins, defined as the condensation 
reaction of a sugar aldehyde or ketone with a free amino goup by nucleophilic addition, leads 
to formation of a Schiff base which rearranges to the Amadori product. In the final step, the 
irreversible advanced glycation end product (AGE) is formed (Brownlee et al., 1990). 
Originally, non-enzymatic glycation reactions involving extracellular proteins and glucose 
were considered to be decisive for the production of AGEs. However, dicarbonyl precursors 
derived from glucose and generated intracellularly have been shown to form AGEs much 
faster suggesting that intracellular hyperglycaemia plays the central role in the formation of 
intracellular as well as extracellular AGEs. The highly reactive dicarbonyl compounds are 
known to be glyoxal, methylglyoxal and 3-deoxyglucosone which are formed from glycolytic 
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intermediates and react with extracellular and intracellular proteins to form AGEs (Wells-
Knecht et al., 1995; Degenhardt et al., 1998). Methylglyoxal arising from glyceraldehyde-3-
phosphate is thought to be the main AGE-precursor in endothelial cells and therefore plays a 
critical role in the development of vascular complications in diabetes mellitus (Bourajjaj et al., 
2003).  
Production of intracellular AGE precursors results in intracellular as well as extracellular 
alterations (Figure 1).  
 
 
 
AGE formation on extracellular matrix proteins has been shown to influence interactions of 
these proteins with their respective receptors (integrins) on cells and other matrix components 
(Brownlee, 2001). Matrix proteins known to be targets of AGE formation are type I and type 
IV collagen as well as laminin. Type IV collagen and laminin are major components of the 
basement membrane and necessary for the maintenance of its normal structure and function. 
Therefore, AGE formation on these proteins impairs matrix-matrix as well as cell-matrix 
interactions (Tanaka et al., 1988; Tsilibary et al., 1988; Charonis et al., 1990). Another 
mechanism induced by binding of AGE modified plasma proteins to AGE receptors leads to 
altered gene expression in endothelial cells, mesangial cells and macrophages. AGE binding 
proteins identified on these cells and targeted by AGE modified plasma proteins are RAGE, 
galectin-3, the macrophage scavenger receptor type II, OST-48 and 80K-H (Neeper et al., 
1992; Vlassara et al., 1995; Smedsrod et al., 1997; Li et al., 1996). Binding to RAGE has been 
found to generate reactive oxygen species (ROS) resulting in the activation of the 
transcription factor NF-κB and p21Ras (Yan et al., 1994; Lander et al., 1997). In mesangial 
cells and macrophages, AGE signalling leads to expression of various cytokines and growth 
factors such as IL-1, TNF-α and TGF-β (Schalkwijk and Stehouwer, 2005). Binding of AGE-
Figure 1. Mechanisms induced 
by production of intracellular 
AGE precursors alter gene 
expression in endothelial cells, 
mesangial cells and 
macrophages. Modifications of 
several proteins including 
intracellular, extracellular matrix 
and plasma proteins by 
intracellular AGE precursors are 
the basis of these alterations 
(Brownlee, 2001). 
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modified proteins to their receptors on endothelial cells induces expression of pro-coagulatory 
and pro-inflammatory molecules known to be thrombomodulin, tissue factor and the vascular 
cell adhesion molecule VCAM-1 (Schmidt et al., 1995; Brownlee, 2001). Furthermore, it has 
been found that AGE signalling in endothelial cells may induce VEGF and therefore seems to 
contribute to diabetes induced hyperpermiability of the capillary wall (Lu et al., 1995). 
The third mechanism contributing to diabetic microvascular diseases leads to activation of 
protein kinase C (PKC). Hyperglycaemia leads to increased formation of the activator of 
PKC, the lipid second messenger diacylglycerol (DAG). The PKC family includes at least 
eleven isoforms. Although DAG has been found to activate almost all of them, its primary 
targets are the β- and δ-isoforms. Hyperglycaemia-induced de novo synthesis of DAG is 
achieved by reduction of the glycolytic intermediate dihydroxyacetone phosphate to glycerol-
3-phosphate followed by acylation reactions (Koya and King, 1998).  
Activation of PKC affects the expression of numerous genes resulting in various structural 
and functional changes typical for microvascular complications in diabetes. Abnormalities in 
blood flow are the result of inhibition of eNOS (Kuboki et al., 2000) and activation of ET-1, 
both mediated by PKC (Glogowski et al., 1999). PKC activation has been found to induce 
VEGF leading to vascular permeability and angiogenesis (Williams et al., 1997). Capillary 
occlusion is the consequence of PKC mediated induction of TGF-β, fibronectin and collagen 
(Koya et al., 1997). PKC activation has been shown to cause vascular occlusion by activation 
of PAI-1 resulting in inhibition of fibrinolysis (Feener et al., 1996). Further genes found to be 
induced as a result of PKC activation are NFκB (Pieper et al., 1997) and NAD(P)H oxidases. 
The former activates expression of pro-inflammatory genes and the latter induces ROS 
leading to multiple effects. 
The fourth biochemical pathway found to be relevant to diabetic microvascular complications 
is the hexosamine pathway. In this pathway, the enzyme glutamine:fructose-6-phosphate 
amidotransferase (GFAT) catalyzes the conversion of the glycolytic intermediate fructose-6-
phosphate to glucosamine-6-phosphate which is subsequently converted into UDP-N-
acetylglucosamine (UDPGlcNAc). UDPGlcNAc is required for O-linked glycosylation of 
proteins catalyzed by the enzyme O-GlcNAc transferase (OGT). Hyperglycaemia-induced 
increased flux through the hexosamine pathway has been found to result in increased 
expression of TGF-β1 (Kolm-Litty et al., 1998) and PAI-1 (Du et al., 2000). The mechanism 
responsible for elevated expression of TGF-β1 and PAI-1 is suggested to increase covalent 
modification of serine and threonine residues of transcription factors such as Sp1 by N-
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acetylglucosamine.  Furthermore, inhibition of eNOS activity has been shown to occur by O-
acetylglucosaminylation at the Akt site of the protein (Du et al., 2001). 
The four biochemical pathways described above have in common that they are activated by 
hyperglycaemia-induced oxidative stress (Figure 2). It has been found that hyperglycaemia 
leads to overproduction of superoxide O2- by the mitochondrial electron transport chain (Du et 
al., 2000). This is the result of hyperglycaemia-induced increased amounts of electron donors 
NADH and FADH2 from the TCA cycle. According to these elevated levels of electron 
donors, the electron flow through the mitochondrial electron transport chain generates a high 
proton gradient across the inner mitochondrial membrane. The consequence of the increased 
mitochondrial membrane potential is a prolonged half-life of superoxide-producing 
ubisemiquinone of the mitochondrial electron transport chain (Brownlee, 2001). The 
overproduction of superoxide has been found to result in activation of the enzyme PARP 
which in turn inhibits the glycolytic enzyme GAPDH by poly-ADP-ribosylation (Du et al., 
2003).  
 
  
  
 
 
 
 
 
 
 
Figure 2. Hyperglycaemia-induced oxidative stress activates four biochemical 
pathways that are known to contribute to vascular complications in diabetes. 
Overproduction of superoxide activates the enzyme PARP which in turn inhibits 
the glycolytic enzyme GAPDH by poly-ADP-ribosylation resulting in 
accumulation of upstream glycolytic metabolites and activation of the four 
biochemical pathways (Schalkwijk and Stehouwer, 2005). 
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3.1.3 Identification of a gene network relevant to diabetic microangiopathy 
 
In contrast to the biochemical mechanisms, there is only little knowledge about the genetic 
factors contributing to the development of diabetic microangiopathy. Therefore, the aim of 
diabetic research is the development of genetic markers for diabetic microangiopathy by 
finding genes that are associated with the occurrence of microvascular complications in 
diabetes (K Dahl-Jørgensen, 1998).  
A cooperation project between the Institute for Pathology and the Complex Systems Research 
Group, both from the Medical University of Vienna, has been initiated, in order to identify a 
functionally relevant gene network critical for diabetic microangiopathy.  
 
3.1.4 Preexisting data 
 
The basis for this network is a set of 125 candidate genes that has been found by gene 
expression profiling comparing (i) BECs derived from tissue samples of diabetic and non-
diabetic patients and (ii) BECs cultured in vitro under diabetic conditions, as well as by 
literature search.  
The aim of identifying a gene network critical for diabetic microangiopathy is to display the 
functional links between the candidate genes representing upregulating and downregulating 
effects as well as autoregulatory mechanisms. 
In order to examine the role of a candidate gene within a supposed gene network the gene has 
to be transiently expressed in an appropriate cell line. Total RNA isolated from cells 
overexpressing a certain gene is converted to cDNA by reverse transcription and applied to 
TaqMan Low Density Arrays spotted with primers and probes for all candidate genes. 
Subsequent quantitative real time PCR enables quantitative detection of PCR products after 
numerous PCR reactions carried out simultaneously according to the number of candidate 
genes. Finally, the upregulating and downregulating effects of a certain transiently expressed 
gene within the candidate gene set on the rest of this set can be measured. According to 
overexpression data, special computer software developed by the Complex Systems Research 
Group is used to create a gene network by reverse engineering. More precisely, a 
mathematical algorithm capable of reconstructing a network comprising a defined number of 
candidate genes is built. In order to identify the functional links between candidate genes 
within an assumed network, the expression of these genes is perturbed in the form of 
overexpression experiments. Gene expression dynamics or changes in expression level with 
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respect to time (dX/dt) of candidate genes within a network resulting from transient 
expression of one candidate gene are described as follows:    
 
dX/dt = f (A, X)  
 
In this formular X comprises all candidate genes within the network (X1, X2, X3…..Xn) and 
the adjacency matrix A represents the functional links between the candidate genes. 
In case of a steady state meaning a state of unaltered gene expression dX/dt can be set equal 
to zero. 
 
3.2 The HOX gene family 
 
3.2.1 General features of HOX genes 
 
Homeobox (HOX) genes encode transcription factors, all of them possessing a so called 
homeodomain that has a DNA binding function. More precisely, the homeodomain is 
responsible for binding to specific sequences within the promoter region resulting in 
transcriptional regulation of the corresponding target genes (Levine and Hoey, 1988).  
A total of 39 HOX genes organized in four clusters named A, B, C and D are found in 
mammals, whereas each cluster is located on a different chromosome. Another feature of 
HOX genes is the existence of 13 paralogue groups. Therefore each cluster is numbered from 
1 to 13. Still, no one contains a full set of HOX genes (Claudia Kappen et al., 1989; Scott, 
1992). Genes of the same group, referred to as trans-paralogues, are equally numbered and 
show a high degree of sequence. They are located on different chromosomes but occupy the 
same relative position. Cis-paralogues are adjacent on the same chromosome, i.e. within the 
same cluster (Greer et al., 2000). In the evolution of HOX genes, two steps occurred, resulting 
in the formation of the existing paralogue groups. In the first step, a primordial homeobox 
gene cluster complex was amplified in cis, whereas the second involved trans-duplication 
(Claudia Kappen et al., 1989). 
 
3.2.2 Function of HOX genes 
 
HOX genes were initially discovered in Drosophila melanogaster where they are known to 
act in anterior-posterior axis patterning during embryogenesis (Lewis, 1978; Ingham, 1988). 
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Further studies carried out with mammalian species have revealed that HOX genes also have 
an important function in adult cells in addition to their roles during embryonic development. 
Genes regulated by HOX transcription factors are critical for a number of cellular processes 
(Figure 3). These are organogenesis, cellular differentiation, cell adhesion and migration, cell 
cycle and apoptosis (Ulijaszek et al., 1998).  
The individual paralogues of HOX genes can have complementary, overlapping or completely 
different functions. As already mentioned trans-paralogues show a high degree of sequence 
homology, and sometimes have a functional overlap, whereas cis-paralogues differ more in 
terms of sequence and function. In some cases, trans-paralogues, such as HOXA3 and 
HOXD3 have been shown to carry out identical functions. Embryonic HOXA3 null mice, 
which are homozygous for the HOXA3 null mutation and therefore do not express any 
HOXA3 protein, experience perinatal lethality that can be rescued by the introduction of 
HOXD3 into the HOXA3 locus. HOXA3 introduced into the HOXD3 locus by homologous 
recombination, has in turn rescued mice homozygous for HOXD3 null mutation, thereby 
preventing skeletal defects of atlas and axis. Interestingly, introduction of HOXA3 into the 
HOXD3 locus does not compensate the effects of homozygous HOXA3 null mutation on 
embryonic development. These data suggest that HOXA3 and HOXD3 can exhibit functional 
equivalence under certain circumstances only, although they do not have identical functions 
under normal conditions. However, the difference in biological functions between trans-
paralogues, such as HOXA3 and HOXD3 does not seem to be a matter of different qualities 
of the respective genes. Otherwise, HOXA3 introduced into the HOXD3 locus would rescue 
embryonic mice, homozygous for HOXA3 null mutation. It is more plausible that their 
differential roles are the result of differences in their expression levels due to cis-acting 
sequences, controlling the expression of the respective loci (Greer et al., 2000; T Svingen and 
KF Tonissen, 2006) 
Figure 3. Mammalian target 
genes of transcription factors 
encoded by HOX genes and 
their respective roles in cellular 
processes. Genes regulated by 
HOX transcription factors are 
critical for a number of cellular 
processes including organo-
genesis, cellular differentiation, 
cell adhesion and migration, cell 
cycle and apoptosis (T Svingen 
and KF Tonissen, 2006). 
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3.2.3 The homeodomain 
 
As mentioned above, highly conserved 60 amino acid motif, the homeodomain, is found in 
transcription factors that are encoded by homeobox genes. Recognizing specific sequences 
within the promoter region of its target genes, this protein domain has a DNA binding 
function enabling transcriptional regulation. The homeodomain is encoded by a 180 base pair 
nucleotide sequence, referred to as the homeobox that is distinctive for homeobox genes 
(Levine and Hoey, 1988; McGinnis and Krumlauf, 1992). 
Three alpha helices forming a helix turn helix motif as well as the N-terminal arm are 
composing the homeodomain (Kuziora and McGinnis, 1989). A high number of 
homeodomain proteins are known to bind specifically to a TAAT core sequence. Interaction 
with DNA is mediated by amino acid residues in the N-terminal arm and third helix. Thereby 
the N-terminal arm interacts with DNA in the minor groove, whereas the third helix contacts 
the major groove (Figure 4). X-ray crystallography and nuclear magnetic resonance 
spectroscopy have been used to come to this conclusion. Basic 
residues 3 and 5, both located on the N-terminal arm have 
been found to contact the nucleotides A2 and T1 respectively 
of the TAAT core sequence. On the third helix, a hydrophobic 
residue numbered 47 and a conserved asparagine (Asn) at 
position 51 have been identified to interact with T4 and A3 
respectively of the DNA recognition sequence (Desplan et. 
al., 1988; Qian et al., 1989; Kissinger et al., 1990; Otting et 
al., 1990).  
 
 
3.2.4 HOXA3 
 
A certain member of the HOX gene family, HOXA3 has been found to be of great importance 
for the development of thymus, thyroid and parathyroid in embryonic mice. Mice 
homozygous for HOXA3 mutation are characterized by the absence of thymus and 
parathyroids, as well as by thyroid hypoplasia. Embryonic HOXA3 is expressed in neural 
Figure 4. Structure of the homeodomain. The homeodomain is composed of an N-terminal 
arm and three alpha helices that form a helix turn helix motif. Amino acid residues in the N-
terminal arm and in helix 3 mediate interaction with DNA in the minor and the major groove 
respectively. Numbers of amino acid residues interacting with theTAAT core sequence are 
shown (T Svingen and KF Tonissen, 2006).
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crest derived mesenchymal cells of the pharyngeal arches and in the pharyngeal endoderm. 
These regions are known to give rise to thymus, thyroid and parathyroid explaining the strong 
influence of HOXA3 on the development of these structures. According to further studies, the 
transcription factors HOXA3 and PAX1 are necessary for the development of thymic 
epithelial cells which interact with thymocytes, in order to promote thymocyte maturation into 
T-cells. Mice heterozygous for HOXA3 and homozygous for PAX1 mutation have defects in 
thymic epithelial cell development. Decreased MHC class II expression and impaired 
capability to promote thymocyte development are typical for thymic epithelial cells of these 
mutants (Manley and Capecchi, 1995; Manley and Capecchi, 1998; Dong-ming Su and 
Manley, 2000). 
Further studies have revealed that HOXA3 expression leads to cell migration in endothelial 
and epithelial cells. The consequence is an activity promoting both, angiogenesis and wound 
closure. Constitutive expression of HOXA3 in an immortalized human dermal microvascular 
endothelial cell line HMEC-1 has shown that HOXA3 causes upregulation of genes involved 
in cell-cell and cell-extracellular matrix (ECM) interactions. These genes, such as uPAR and 
MMP-14 are important for an increase of the angiogenic potential of endothelial cells by 
degradation of ECM-constituents. HOXA3 has been found to be upregulated in wounded 
tissues of mice, where it promotes angiogenesis in order to initiate wound repair. 
Interestingly, further studies have revealed a lack of HOXA3 in wounds of diabetic mice. 
However, transfer of HOXA3 expression plasmids into the wounded diabetic tissue has 
resulted in upregulation of uPAR and MMP-14, leading to accelerated wound closure. These 
data suggest a therapeutic value of HOXA3 for diabetic patients via its activity in endothelial 
cells (Kimberly et al., 2005). 
HOXA3 also seems to play a role in diabetic microangiopathy, a process characterized by 
thickening of the capillary basement membrane of patients suffering from diabetes mellitus. A 
candidate gene set containing 125 genes, including HOXA3 has emerged to be of relevance to 
diabetic microangiopathy. This gene set has been identified by gene expression profiling 
comparing (i) BECs derived from tissue samples of diabetic and non-diabetic patients and (ii) 
BECs cultured in vitro under diabetic conditions, as well as by literature search. HOXA3 has 
been found to be upregulated under diabetic conditions (Nikolaus Wick et al., unpublished 
data). Furthermore, HOXA3 constitutively expressed in HMEC-1 leads to upregulation of   
collagen, type VI, alpha 1 (Kimberly et al., 2005).  Thickening of the capillary basement 
membrane during diabetic microangiopathy is characterized by increases in type IV and type 
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VI collagen (Williamson JR, Tilton RG et al., 1988), suggesting a possible significance of 
HOXA3 for this process.  
One aim of this diploma thesis is to report the role of transcription factor HOXA3 in diabetic 
microangiopathy by examining its effects upon transient expression in immortalized human 
umbilical vein endothelial cells (iHUVECs) on the genes within the candidate set. Another 
aim is to identify the position of the HOXA3 gene in a gene network that is assumed to be of 
relevance to diabetic microangiopathy. 
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4 Materials and methods 
 
4.1 Buffers and solutions 
 
4.1.1 Buffers and solutions for molecular biological methods 
 
LB (Luria Broth) medium 
10 g Bacto-tryptone (DIFCO, USA, cat. no. 211705) 
5 g Bacto-yeast extract (DIFCO, cat. no. 212750) 
10 g NaCl 
1N NaOH was added until pH was adjusted to 7.5. 
Water was then added to a final volume of 1000 ml. Finally, medium was autoclaved and 
cooled down to 50-55°C. 
 
LB (Luria Broth) agar plates 
700 ml LB medium (see above) 
10.5 g agar (DIFCO, cat. no. 281230) 
The mixture was autoclaved and cooled down to 50-55°C.  
Antibiotics (30 μg/ml ampicillin, chloramphenicol or kanamycin) were added at a ratio of 
1:1000 (700 μl) to yield a final concentration of 30 μg/μl. Afterwards, 20-30 ml volumes of 
medium were transferred into Petri dishes and the plates were stored at 4°C. 
 
TENS lysis buffer (Plasmid preparation method “Genevieve”) 
0.5 ml 1M TRIS-HCl pH 8 (10mM) 
100 μl 0.5M EDTA (1mM) 
5 ml 1N NaOH (0.1N) 
1.15 ml 20%SDS 
43.25 ml Distilled water  
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4.1.2 Buffers and solutions for cell biology methods 
 
Molecular weights 
Tris: 121.14 g; Glycine: 75.07 g; EDTA: 380.2 g; DTT: 154.25 g; 
 
1 x PBS (Washing buffer) 
0.20 g KCl 
0.20 g KH2PO4 
1.15 g Na2HPO4 
8.00 g NaCl 
Distilled water was added to a final volume of 1000 ml. HCl was used to adjust pH 7.4. 
 
0.1% Triton X-100 
50 μl Triton X-100 
Addition of 1 x PBS to a final volume of 50 ml 
 
4.1.3 Buffers and solutions for SDS-PAGE/Western blot 
 
1M Tris-HCl pH 6.8/8.8 
121.14 g Tris base 
1000 ml of double distilled water 
Addition of HCl until pH 6.8/8.8 was adjusted 
 
Laemmli Buffer 
6.25 ml of 1M Tris-HCl, pH 6.8 (62.5 mM) 
2.35 g SDS (2.35%) 
0.038 g EDTA (1 mM) 
10 ml Glycerol (10%) 
0.001 g Bromphenol blue 
1.543 g DTT (100 mM) 
Water was added to a volume of 1000 ml. Laemmli Buffer containg DTT was aliquoted and 
stored at -20°C.  
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12% Acrylamid gel  
3.3 ml Distilled water 
4.0 ml 30% Acrylamid BIS (29:1, BioRad) 
2.5 ml Tris-HCl, pH 8.8 
0.1 ml 10% SDS 
0.1 ml 10% APS 
4.0 μl TEMED (N,N,N',N'-Tetramethylethylenediamine) 
 
Stacking gel 
3.4 ml Distilled water 
830 μl 30% Acrylamid BIS (29:1, BioRad) 
630 μl Tris-HCl, pH 6.8 
50 μl 10% SDS 
50 μl 10% APS 
5 μl TEMED (N,N,N',N'-Tetramethylethylenediamine) 
 
10 x Electrophoresis buffer for SDS-PAGE 
360.325 g Glycin (192 mM) 
75.7125 g Tris (25 mM) 
25 g SDS (0.25%) 
Distilled water was added to a volume of 2500 ml. For electrophoresis 10 x electrophoresis 
buffer was diluted 10 fold.  
 
Transfer buffer for Western blot 
36.034 g Glycine (192 mM) 
7.571 g Tris (25 mM) 
500 ml Methanol (20%) 
Distilled water was added to a volume of 2500 ml and pH was adjusted to 8.5. 
 
Ponceau S Red 
0.1 % Ponceau S Rot in distilled water 
5 % Acetic Acid 
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10 x TBS (Tris Buffered Saline) 
24.5 g Tris 
80.0 g NaCl 
Distilled water was added to a volume of 1000 ml and pH was adjusted to 7.6 
 
1 x TBS with Tween (TBST) 
900 ml Distilled water 
1 ml Tween-20 
100 ml 10 x TBS 
 
Blocking buffer (5% milk powder in TBST) 
5 ml 10 x TBS 
45 ml distilled water 
2.5 g nonfat dry milk (5%) 
50 μl Tween-20 
 
Antibody dilution buffer (2.5% milk powder in TBST) 
2 ml 10 x TBS 
18 ml distilled water 
0.5 g nonfat dry milk (2.5%) 
20 μl Tween-20 
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4.2 Cloning vectors 
 
Two cloning vectors (Figure 5) were used for cloning the coding sequence of the HOXA3 
gene: 
 
  
Figure 5. Cloning vectors used for cloning the coding sequence of the HOXA3 gene were 
pCR® II TOPO® (5a) and pIRES2-EGFP (5b). 
 
After PCR, the coding sequence of the HOXA3 gene was subcloned into the pCR® II 
TOPO® vector (Figure 5a) that was purchased from Invitrogen. Topoisomerase I isolated 
from Vaccinia virus is covalently attached to the plasmid vector. After recognizing the 
specific sequence CCCTT on one strand, the enzyme binds to duplex DNA where it cleaves 
the phosphodiester backbone after the last thymidine (T) of the recognition sequence 
(Shuman, 1991). Topoisomerase I activity on both strands of the pCR® II TOPO® vector 
generates single 3`-thymidine (T) overhangs. PCR products generated by Taq polymerase 
possess single deoxyadenosines (A) at their 3`ends enabling insertion into pCR® II TOPO®. 
DNA-cleavage by topoisomerase I results in covalent attachment of the enzyme to the 
3`phosphate of the cleaved strand of the plasmid vector, as mentioned above. Release of 
topoisomerase I is achieved by nucleophilic attack of the 5`hydroxyl of the broken strand. 
Therefore, PCR products require 5`hydroxyl instead of 5`phosphates for successful ligation 
into the vector (Shuman, 1994). 
The pCR® II TOPO® vector has a molecular size of 4.0 kb and contains two antibiotic 
resistance marker genes that provide resistance to kanamycin and ampicillin. Furthermore, a 
pUC origin of replication confering propagation in E.coli and an f1 origin for synthesis of 
single stranded DNA are located on the plasmid vector.  
A B 
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The multiple cloning site resides within the sequence of the lacZα gene that is connected to 
the lac promoter. Cloning a DNA sequence into the multiple cloning site leads to interruption 
of the lacZ sequence resulting in a loss of function of the lacZα gene to produce the protein 
beta galactosidase. The fact that beta galactosidase turns its substrate X-gal into a blue dye is 
used to select for cells that contain plasmid vectors with an interrupted multiple cloning site. 
In case of successful cloning of a coding sequence into pCR® II TOPO®, transformed cells 
remain white in presence of X-gal due to interruption of the lacZα gene. Blue stained cells 
possess a functional lacZα gene that turns X-gal into a blue dye. IPTG inactivates the lac 
repressor resulting in activation of the lac operon. Therefore, addition of IPTG is necessary in 
order to enable the blue/white selection method. 
The coding sequence of the HOXA3 gene was cloned into the expression vector pIRES2-
EGFP (Figure 5b) purchased from Clontech Laboratories, Inc., in order to study transient 
overexpression of HOXA3 in immortalized human umbilical vein endothelial cells 
(iHUVECs). The characteristic of pIRES2-EGFP is the presence of the internal ribosomal 
entry site (IRES) of the encephalomyocarditis virus (ECMV). On the expression vector, the 
internal ribosomal entry site is located between the multiple cloning site and the coding region 
of the enhanced green fluorescent protein (EGFP). This construction enables translation of the 
gene that is cloned into the multiple cloning site and the EGFP gene from a single bicistronic 
mRNA. The multiple cloning site itself is located between the immediate early promoter of 
cytomegalovirus (PCMV IE) and the IRES sequence  
Expression of the EGFP gene indicates successful transfection into iHUVECs and other 
eukaryotic cells with pIRES2-EGFP carrying the gene of interest. However, it is important to 
note that synthesis of the EGFP protein does not require cloning of a gene into the multiple 
cloning site of the expression vector. Therefore, pIRES2-EGFP may be used for control 
transfection. Processing of the bicistronic mRNA is directed by SV40 polyadenylation signals 
located downstream of the EGFP gene. Furthermore, pIRES2-EGFP contains an SV40 origin 
conferring replication in eukaryotic cells expressing the SV40T antigen.  
Another feature of pIRES2-EGFP is the presence of both, a pUC origin of replication 
enabling propagation in E.coli and an f1 origin for synthesis of single stranded DNA. 
Antibiotic resistance genes confer resistance to kanamycin and neomycin (BD Biosciences 
Clontech).  
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4.3 Molecular biology methods 
 
Bacterial cultures 
DH10B TonA cultures transformed with plasmid pCMV-Sport6 carrying the HOXA3 gene 
were purchased as glycerol stock from Invitrogen (cat. no. 3905733). Before starting a PCR, 
overnight cultures had to be grown by combining 1.0 µl aliquots of the glycerol stock with 4 
ml of LB-medium. In order to select for cells containing the pCMV-Sport6 plasmid the 
antibioticum ampicillin (100 mg/ml) was added at a ratio of 1:1000 to the mixture (final 
concentration of Ampicillin:100 μg/ml). 
 
Plasmid DNA isolation (plasmid “miniprep”) 
Plasmid miniprep was done for 1.5 ml of each bacterial over night culture. After a quick spin 
in the Eppendorf Microcentrifuge at 10,000 rpm and following disposal of the supernatant the 
remaining cell pellet was dissolved in 300 µl of TENS and 150 µl of 3M potassium acetate to 
cause cell lysis. Then, the lysate was centrifuged for 2 min. at 13,000 rpm (17,900 x g) and 
the supernatant was transferred into a fresh tube. After adding 900 µl of 96% ethanol the 
resulting mixture was put on -80°C for 30 min. Afterwards the solution was centrifuged for 20 
min. at 4°C and the supernatant was removed. The remaining cell pellet was washed with 900 
µl of 70% ethanol and the resulting solution was centrifuged again for 2 min. at 13,000 rpm. 
After removing the ethanol the pellet was air dried and dissolved in 50 µl DNase free water.     
 
Restriction digestion of pCMV-Sport6 
After elution of plasmid DNA in 50 μl DNase free water a restriction digest of an aliquot of 
5.0 μl and subsequent gel electrophoresis on 1 % agarose gel containing ethidium bromide 
were executed in order to control the success of pCMV-Sport6 isolation and to check whether 
the plasmids carried the right insert. The restriction endonucleases NheI (recognition 
sequence: GCTAGC) and StuI (recognition sequence: AGGCCT) were used to cut the insert 
out of pCMV-Sport6. All reagents used for digestion were purchased from New England 
BioLabs Inc.  
The composition of the 20 μl reaction mix was as follows: 
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?   5.0 μl…….DNA 
?   0.5 μl…….RNase 
?   1.0 μl…….StuI 
?   1.0 μl…….NheI 
?   0.2 μl…….BSA (at a ratio of 1:100 to the total volume) 
?   2.0 μl…….10 x buffer (NEBuffer 2; at a ratio of 1:10 to the total volume) 
? 10.3 μl…….Water (aqua dest.) 
 
The reaction mix was incubated for 1-2 hours at 37°C. Before the samples were applied to the 
gel, 5.0 μl of loading dye were added.  
 
PCR of HOXA3 
Primers for the PCR reaction (also from Invitrogen) were designed with the aid of the 
OligoPerfect™ Designer program provided by Invitrogen. Primers were designed 
corresponding to the start and the end of the coding sequence of the HOXA3 gene to ensure 
that only the coding sequence was amplified during the PCR reaction. Restriction enzyme 
sites were added to the 5`ends of both, forward and reverse primer. Forward primer contained 
a restriction site for XhoI (CTCGAG) and an additional 5`CAGT extension leading to a 
primer sequence as follows: 5`-CAGTCTCGAGATGCAAAAAGCGACCTACTA-3`, 
whereas reverse primer possessed a restriction site for SalI (GTCGAC) and an additional 
5`CAGT extension yielding the primer sequence 5`-
CAGTGTCGACTCACAGGTGGGTGAGCTTG-3`. Primers diluted 1:10 in distilled water 
were added to the PCR reaction mix. Primer extension was catalyzed by Taq Polymerase 
purchased from Pharmacia.  PCR was meant to deliver products containing the recognition 
sequence for XhoI (CTCGAG) on their 5` ends and the recognition sequence for SalI 
(GTCGAC) on their 3`ends. The whole 50 µl PCR reaction mix was composed of as follows: 
 
?   0.5 µl…….DNA 
?   2.0 µl…….dNTPs 
?   3.0 µl…….Rapid load 
?   5.0 µl…….PCR 10 x buffer (Pharmacia) 
?   2.0 µl…….Primer (from 1:10 dilution) 
?   0.5 µl…….Taq polymerase (5000 U/ml; Pharmacia) 
? 37.0 µl…….Water (aqua dest.)  
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The PCR program was as follows: 
 
95°C     5 min. 
76°C     2 min. (Addition of Taq polymerase) 
95°C     1 min. 
60°C     1 min. 
72°C   90 sec. 
72°C   10 min. 
  4°C    forever 
 
PCR was performed by GeneAmp PCR System 9600 for 40 cycles. The expected 1.3 kb PCR 
product was visualized by electrophoresis on 1% agarose gels containing ethidium bromide.  
 
Extraction of the PCR products from the agarose gel and purification  
Extraction and purification of the 1.3 kb PCR products were executed using the QIAquick® 
PCR Purification Kit from QIAGEN (cat. no. 28104). Three volumes of gel dissolving buffer 
QG were added to the excised gel slice containing the DNA of interest. The resulting mixture 
was incubated at 50 °C until the gel was completely dissolved. Then 1 gel volume of 
isopropanol was added and the resulting solution was mixed by vortexing. Afterwards the 
solution was applied to a QIAquick spin column in a 2.0 ml collection tube. In order to bind 
DNA to the silicia membrane of the spin column the mixture was centrifuged for 1 min. at 
13,000 rpm. After removing the flow-through, bound DNA was washed with 750 µl of Buffer 
PE and centrifuged again for 1 min. at 13,000 rpm. Then the QIAquick spin column was 
placed into a fresh 1.5 ml tube and DNA was eluted by adding 30 µl of distilled water to the 
center of the silicia gel membrane and further centrifugation for 1 min. at 13,000 rpm. 
 
Ligation of DNA into pCR® II TOPO® vector 
Purified PCR products were subcloned into the pCR® II TOPO® vector according to the 
protocol of the TOPO TA cloning® kit from Invitrogen.  
 
? 2.0 µl…….DNA (PCR product) 
? 1.0 µl…….Salt solution 
? 2.0 µl…….Water (aqua dest.) 
? 1.0 µl…….pCR II TOPO vector 
40 cycles 
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Both, TOPO vector and salt solution were components of the cloning kit. Incubation time of 
the ligation mix was up to 30 min. 2µl of the ligation mix were used for transformation of 
E.coli DH5α. 
 
Transformation of E.coli DH5α 
For transformation One Shot® MAX Efficiency® DH5 α ™ Chemically Competent Cells 
(cat.no.12297-016) purchased from Invitrogen were used. After the cells were put on ice, 2-6 
µl of the ligation reaction were added. The cells were incubated on ice for 30 min. before a 
heat shock of 30 sec. at 42°C was executed. In the next step 250 μl of SOC-medium (pre 
warmed at 37°C) were added to the cells and the resulting mixture was shaken at 37°C and 
225 rpm for 1 h. Afterwards, the mixture was plated onto LB-plates supplemented with 
kanamycin. The plates were incubated at 37°C overnight. Next day single colonies were 
picked from the plates by pipette tips and overnight cultures were started by placing the tips 
into tubes containing 4.0 ml LB-medium and adding kanamycin (30 mg/ml) at a ratio of 
1:1000 (final concentration of kanamycin:30 μg/ml). Isolation of plasmids carrying the gene 
of interest was done according the plasmid miniprep protocol as described above. 
 
Restriction digestion of TOPO vectors 
DNA ligated into pCR® II TOPO® vector was supposed to contain the recognition sites for 
endonucleases XhoI (CTCGAG) and SalI (GTCGAC) on the 5`end and the 3`end 
respectively. In order to cut the DNA of interest out of the TOPO vector a restriction digest 
using the endonucleases XhoI and SalI was performed. The restriction endonucleases were 
meant to create sticky ends for ligation into the vector pIRES2-EGFP. The composition of the 
reaction mix was as follows: 
 
? 30.0 μl…….DNA 
?   1.0 μl…….RNase 
?   1.5 μl…….XhoI 
?   1.5 μl…….SalI 
?   0.5 μl…….BSA (at a ratio of 1:100 to the total volume) 
?   5.0 μl…….10 x buffer (NEBuffer 2; at a ratio of 1:10 to the total volume) 
? 10.5 μl…….water (aqua dest.) 
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All reagents used for digestion were purchased from New England BioLabs Inc. The 
digestion was carried out for at least 3 h up to 16 h. Before the reaction mix was applied to the 
1% agarose gel containing ethidium bromide, 5.0 μl of loading dye were added. 
The expected 1.3kb products were extracted and purified according to the protocol of 
QIAquick® PCR Purification Kit from QIAGEN (cat. no. 28104). 
 
Ligation of DNA into pIRES2-EGFP and transformation of E.coli DH5α 
HOXA3 DNA possessing sticky ends created by restriction digestion with the restriction 
endonucleases XhoI and SalI had to be cloned into the multiple cloning site of the expression 
vector pIRES2-EGFP (Clontech Laboratories Inc., CA, USA, discontinued). In order to 
ensure ligation, the expression vector needed to have sticky ends compatible to those of the 
HOXA3 insert. Thus the empty vector had to be treated with the same restriction 
endonucleases as the HOXA3 gene. Ligation of the coding sequence of HOXA3 into pIRES2-
EGFP was catalysed by T4 DNA-ligase (Invitrogen). The ligation reaction mix was composed 
of: 
 
?   6.0 μl…….HOXA3 DNA 
?   2.0 μl…….pIRES2-EGFP 
?   1.0 μl…….10 x ligase buffer 
?   1.0 μl…….T4 DNA-Ligase 
 
Ligation was executed at 16 °C overnight. Transformation of E.coli DH5α was done with 5 μl 
of ligated DNA as described above. 
 
Capillary sequencing 
Capillary sequencing was performed in order to control, whether pIRES2-EGFP was carrying 
the coding sequence of the HOXA3 gene. First, cycle sequencing reactions were executed to 
generate ddNTP labelled DNA fragments which could be detected afterwards by the ABI 
Prism 377 sequencing detection system. Primers used for the cycle sequencing reaction were 
pIRES sequencing forward and reverse primer purchased from Invitrogen. The composition 
of the cycle sequencing reaction mix was as follows: 
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? 5.0 μl…….Water (aqua dest.) 
? 2.0 μl…….Primer (pIRES sequencing forward or reverse primer) 
? 2.0 μl…….Big Dye TM Reaction Mix (Applied Biosystems) 
? 1.0 μl…….DNA      
 
For each sample that had to be sequenced two cycle sequencing reaction mixes were prepared 
which differed in added primers. One mix contained pIRES sequencing forward primer 
whereas the other cycle sequencing reaction mix contained pIRES sequencing reverse primer. 
DNA polymerase needed for primer extension as well as ddNTPs were contained in the added 
Big Dye TM Reaction Mix. 
Cycle sequencing reaction program: 
 
96°C     1 min. 
96°C   12 sec.                                                   
56°C     7 sec.            
60°C     2 min.  
  4°C     forever 
 
After finishing the cycle sequencing reaction unincorporated ddNTPs were removed from the 
reaction mix by using the DyeEx 2.0 Spin Kit (cat. no. 63206) purchased from QIAGEN. 
Columns filled with Sephadex G50 were used to remove unbound ddNTPs. DNA fragments 
labelled with ddNTPs were eluted in 20 μl of water. Before sequencing was finally started 20 
μl of formamide were added to the samples. 
 
Endotoxin free plasmid midipreparation 
Endotoxin free plasmid midipreparation was executed using the QIAfilterTM Midi Kit (25) 
from QIAGEN (cat. no. 1224). Initially, 5 μl of the glycerol stock of transformed bacterial 
cells were added to 50 ml LB medium supplemented with 50 μl kanamycin. The resulting 
mixture was incubated on a shaker at 37°C and 225 rpm overnight. The next day, the bacterial 
cell suspension was centrifuged for 20 min. at 6000 x g at 4°C and the resulting bacterial cell 
pellet was dissolved in 4 ml of RNase A-containing buffer P1. After addition of lysis buffer 
P2 and an incubation time of 5 min., neutralization buffer P3 was added. The resulting 
mixture was poured into the barrel of a QIAfilter Cartridge and after 10 min. of incubation the 
cell lysate was filtered into a 50 ml Falcon tube. In the next step, 1ml buffer ER was added to 
29 cycles 
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the filtered lysate and after 30 min. of incubation on ice, the lysate was applied to an 
equilibrated QIAGEN tip where the plasmid DNA was expected to bind to anion-exchange 
resin. The QIAGEN tip was then washed twice with 10 ml buffer QC. Elution of plasmid 
DNA was executed with 5 ml of buffer QN. The eluted DNA was collected in a 10 ml 
endotoxin free polyallomer tube. After addition of 3.5 ml room-temperature isopropanol to 
the eluate in order to achieve precipitation of plasmid DNA, the mixture was centrifuged for 
30 min. at 15,000 x g and 4°C. The resulting DNA pellet was washed with 2 ml of endotoxin 
free room-temperature 70% ethanol. After further centrifugation for 10 min. at 15,000 x g 
followed by removal of the supernatant, DNA was dissolved in 100 μl of endotoxin free 
water. Finally, DNA concentration was measured as described below. Endotoxin free DNA 
obtained from endotoxin free plasmid midipreparation was used for transfection of iHUVECS 
in order to study transient overexpression of the HOXA3 gene in an endothelial cell line.  
 
Spectrophotometric measurement of DNA concentration 
.A U-2000 Spectrophotometer (Hitachi) was used to determine DNA concentration of a 
sample by measuring the optical density (absorbance) at 260 nm. Before measurement, 
dilution of the sample was executed at a ratio of 1:200 by adding 3 μl of the sample to 600 μl 
of DNase free water.  
The measured absorbance was used to determine DNA concentration according to the 
formula:  
c [μg/ml] =  OD260 x D x F 
c  ….Concentration of DNA (μg/ml) 
OD260  ....Absorbance (optical density) at 260 nm 
D  ….Dilution used 
F  ….Strandedness of DNA (50 for dsDNA) 
 
Measurement of DNA concentration was executed in order to use appropriate amounts of 
endotoxin free DNA for transfection of iHUVECs. 
 
Total RNA isolation from transfected cells 
Cells successfully transfected with pIRES2-EGFP carrying the gene of interest were 
centrifuged for 2 min. at 2,800 rpm and 4 °C. The cell pellet was then dissolved in 1ml of 
RLT buffer supplemented with 1% β-mercaptoethanol. In preparation for total RNA isolation, 
the mixture was applied to QIAshredderTM (50) from QIAGEN (cat. no. 79654) in order to 
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homogenize the cell lysate by centrifugation for 2 min. at 13,000 rpm. Total RNA isolation 
was executed using the Rneasy® Mini Kit (50) from QIAGEN (cat. no. 74104). In the 
beginning, 350 μl of RNase-free 70 % ethanol were added to the homogenized sample and the 
resulting mixture was applied to an RNeasy spin column. The loaded RNeasy spin column 
was centrifuged for 2 min. at 13,000 rpm in order to achieve binding of total RNA to the 
silicia gel membrane. Buffer RW1 was used to wash RNA bound to the silicia gel membrane 
and to remove unwanted excess material. Degradation of unwanted genomic DNA was 
accomplished by incubation of the silicia gel membrane with DNase I diluted with buffer 
RDD at a ratio of 1:8. Two further washing steps were carried out using buffer RPE before 30 
μl of RNase-free water were added to elute RNA. 
 
Reverse transcription  
Reverse transcription of total RNA isolated from successfully transfected iHUVECs was 
carried out in order to produce cDNA that was applied to TaqMan Low Density Custom 
Arrays for high throughput real time PCR. 
For reverse transcription 20 μl of total RNA were added to SprintTM PowerScriptTM PrePrimed 
Single Shots (Clontech) containing lyophilized master mix composed of reverse transcriptase, 
random hexamer or oligo(dT)18 primers (20 μM), BSA (10mg/ml), DTT (1M), dNTP mix 
(10mM each), 10x reaction buffer, cryoprotectant and stabilizers. Reverse transcription was 
carried out using GeneAmp PCR System 9600.  
The thermal cycler program for reverse transcription was as follows: 
 
 42 °C     90 min. 
 70 °C     10 min. 
   4 °C      forever 
 
Multiplex PCR 
Multiplex PCR was executed in order to control the quality and integrity of cDNAs produced 
by reverse transcription. The four housekeeping genes BCR, β2-microglobulin, ABL and 
PBGD were chosen for amplification. Multiplex PCR was carried out using AmpliTaq Gold®, 
5 x 1000 U, with GeneAmp® 10X PCR Gold Buffer and MgCl2 Solution from Applied 
Biosystems (cat. no. 4311818). Furthermore, GeneAmp dNTPs, also purchased from Applied 
Biosystems, (cat. no. N808-0007) were added to the PCR reaction mix. Primer pairs for the 
four housekeeping genes were mixed together and diluted at a ratio of 1:10. 
1 cycle 
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The multiplex PCR reaction mix was composed of as follows: 
 
? 32.75 μl…….Water (aqua dest.) 
?   5.0   μl…….10X PCR Gold Buffer 
?   3.0   μl…….MgCl2 Solution (1.5 mM) 
?   4.0   μl…….dNTPs (final concentration 200 μM) 
?   3.0   μl…….Rapid load 
?   0.25 μl…….AmpliTaq Gold® (1.25 Units) 
?   1.0   μl…….Primer (from 1:10 dilution, final concentration: 2 μM) 
?   1.0   μl…….cDNA 
 
The thermal cycler program for multiplex PCR was as follows: 
 
95°C     5 min. 
95°C     1 min. 
56°C     1 min. 
72°C     90 sec. 
  4°C     forever 
 
GeneAmp PCR System 9600 was used in order to perform multiplex PCR. The sample was 
applied to a 2% agarose gel containing ethidium bromide and the PCR products were 
separated according to their length (BCR: 377 bp, β2-microglobulin: 287 bp, ABL: 193 bp, 
PBGD: 128 bp) by agarose gel electrophoresis. 
 
High throughput real time PCR 
The aim of high throughput real time PCR was to investigate the effects of overexpression of 
the HOXA3 gene on the expression of 125 candidate genes relevant to diabetic 
microangiopathy. TaqMan® Low Density Custom Arrays (Applied Biosystems) were 
constructed in order to enable 128 simultaneous quantitative real time PCR reactions. More 
precisely, 128 candidate gene specific primers and probes were spotted onto a total of two 
micro-fluidic cards referred to as DMA1 and DMA2. Each of these 384-well micro-fluidic 
cards contained two series of 64 pre-made assays that were applied in triplicates. GAPDH 
specific primers and probes were located on both TaqMan® Low Density Custom Arrays. In 
addition, DMA2 contained assays for the housekeeping genes NARS and TARDBP which 
40 cycles 
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were not part of the candidate gene set but were chosen for normalization as described below. 
Thus, both TaqMan® Low Density Custom Arrays comprised a total of 128 pre-made assays 
(Table 1).  
For quantitative real time PCR 100 μl of a reaction mix composed of 20 μl cDNA, 405 μl 
water (Aqua dest.) and 425 μl 2 x TaqMan Universal PCR Master Mix were applied to 4 from 
8 loading ports of DMA1 and DMA2 respectively. Subsequent centrifugation of the micro-
fluidic cards at 330 g for 2 min. was executed in order to achieve migration of the samples 
into the wells. Finally, high throughput PCR was carried out using the ABI Prism 7700 
sequence detection system (Applied Biosystems).  
 
Table 1. List of candidate genes that were represented in the form of pre-made assays 
spotted on TaqMan® Low Density Custom Arrays. 
Number Gene symbol Number Gene symbol Number Gene symbol Number Gene symbol 
1 ABL2 33 EBF 65 MAP4 97 PTK2 
2 ACE 34 EGF 66 MAPK11 98 PXN 
3 ADH1A 35 EPHA4 67 MAPK12 99 RAMP3 
4 ADH1B 36 ET 68 MAPK14 100 RHOJ 
5 AGT 37 F2 69 MCFP 101 RPIB9 
6 ALDOA 38 FBXO7 70 MINPP1 102 RPL13 
7 ANGPT1 39 FGF1 71 MMP2 103 RPLP0 
8 ANGPT2 40 FLT1 72 MMP9 104 SERPINE1 
9 AQP1 41 FN1 73 MT1A 105 SLC2A1 
10 ARF4 42 FZD4 74 NARS 106 SLCO2B1 
11 ATP6 43 GAPDH 75 NDST1 107 SMAD2 
12 BCL2 44 GAPDH 76 NFKB1 108 SMAD3 
13 BMX 45 GCA 77 NOP5/NOP58 109 SOD1 
14 BTF3 46 GDI2 78 NOS3 110 SORBS1 
15 C13orf10 47 GJA1 79 NOX5 111 SRRM1 
16 C1S 48 GNAS 80 OASL 112 STAT3 
17 C7 49 GTPBP4 81 OSBPL10 113 STOM 
18 CALM2 50 HOXA3 82 OSBPL1A 114 TAF7 
19 CASP3 51 HPN 83 PARK7 115 TARDBP 
20 CD59 52 ICAM1 84 PARP1 116 TGFB1 
21 CDYL2 53 IER3 85 PCK1 117 TGFBR2 
22 CFH 54 IGF1 86 PCK2 118 TH1L 
23 CFL1 55 IGF2 87 PDGFA 119 THBD 
24 CMAH 56 IL8 88 PHGDH 120 TIMP2 
25 COL4A1 57 ITGA1 89 PLAGL1 121 TNC 
26 CRP 58 ITM1 90 PLD1 122 TOR3A 
27 CSPG2 59 JUN 91 PPAP2A 123 UBE4A 
28 CTGF 60 KLF6 92 PPP1CB 124 UGDH 
29 CTSZ 61 LAMB1 93 PRG1 125 USP34 
30 CXCL12 62 LEPR 94 PRKACA 126 VCAM1 
31 CYR61 63 LEREPO4 95 PRKCB1 127 VEGF 
32 DGKE 64 LMCD1 96 PRSS23 128 VIM 
GAPDH specific primers and probes were found on DMA1 as well as DMA2. Housekeeping 
genes NARS and TARDBP were chosen for normalization.  
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4.4 Bioinformatics 
 
Analysis of data obtained from high throughput real time PCR 
Tresholds were set manually within regions of linear increase of sigmoid curves generated by 
analysis of high throughput real time PCR with SDS 2.2 software (Applied Biosystems). 
Finally, data were exported and calculation of the fold change was done using the ΔΔCt 
method. In the beginning, Ct values of the sample were normalized to Ct values of GAPDH, 
in order to compensate differences in measurements of the sample between DMA1 and 
DMA2. Ct values normalized to those of GAPDH were then normalized to Ct values of two 
housekeeping genes (NARS and TARDBP) in order to be able to compare overexpression 
experiments carried out with different genes. Finally, Ct values of the sample were compared 
to those of the calibrator sample obtained by transfection of iHUVECs with the empty vector. 
Building the difference between the sample to be measured and the calibrator sample allowed 
for determining the fold change ratio. 
 
Construction of a gene network relevant to diabetic microangiopathy 
The fold change ratio (FC) was determined according to the formula: 
FC = 2-ΔCt = xij/xi0  
xi0     …gene expression of the i-th gene  
xij      …gene expression of the i-th gene when the j-th gene is perturbed 
Next, the influence matrix (D) was built in order to describe the effect of perturbation of gene 
j on the expression of gene i: 
Dij = ln (xij/xi0) 
Building of D was expected to yield one of the three possible results: 
 
Dij =   
 
The next step was carried out according to following consideration: In a given gene network 
represented by the adjacency matrix (A) it was necessary to find all the direct and indirect 
regulatory links between gene i and gene j. The connection between the influence matrix (D) 
and adjacency matrix (A) is given with the following equation: 
 
Aji = ln (D+I), where ln(D+I) is a matrix logarithm.         
> 0     …perturbation of gene j leads to overexpression of gene i 
< 0     …perturbation of gene j leads to downregulationof gene i 
= 0     …perturbation of gene j has no effect on the expression of gene i  
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Finally, a threshold was set, corresponding to in advance given network connectivity, to select 
significant link weights. The non-significant ones, below the threshold, were set to zero.  
 
4.5 Cell biology methods 
 
Cells 
Immortalized human umbilical vein endothelial cells (iHUVECs) were a kind gift from 
Professor Miertinnen (University of Helsinki, Finland). These cells were immortalized with 
the human telomerase catalytic protein (hTERT). Immortalized human umbilical vein 
endothelial cells have previously been shown to largely maintain their endothelial character, a 
property necessary for the studies of diabetic microangiopathy. Another reason for choosing 
iHUVECs was technical feasibility including a reasonable transfection efficiency (30-75 % 
with pIRES2-EGFP) that would be important for later transfection studies. Cells were 
maintained in RPMI 1640 medium (GIBCO, cat. no. 51800-035) supplemented with 10 % 
FBS (fetal bovine serum, GIBCO, cat. no.10108-157) and 1% penicillin/streptomycin 
(GIBCO, cat. no.15140-122). Incubation of iHUVECs was carried out at 37 °C in an 
incubator with a CO2 content of 5 % and 90 % relative humidity. 
 
Transfections 
Transfection was carried out when iHUVECs maintained in in RPMI 1640 medium (GIBCO, 
cat. no. 51800-035) supplemented with 10 % FBS (fetal bovine serum, GIBCO, cat. 
no.10108-157) and 1% penicillin/streptomycin (GIBCO, cat. no.15140-122) were grown to 
90-95% confluence. The amount of endotoxin free plasmid DNA, Lipofectamine2000TM 
(Invitrogen, cat. no. 11668-027) and OptiMEM® (Invitrogen) used for successful transfection 
was adapted according to the effective growth area of the culture dishes where the cells were 
grown. At the beginning, endotoxin free plasmid DNA (0.4 μg/cm2) and the cationic lipid-
based reagent Lipofectamine2000TM (0.5 μl/cm2) were separately incubated in tubes 
containing OptiMEM® (25 μl/ cm2) for 5 min. at room temperature. Prior to transfection, the 
contents of both tubes were combined and incubated at least for further 20 min. at room 
temperature. The transfection mix was then added to the grown cells and after 2-4 h of 
incubation at 37°C the mixture was removed and RPMI 1640 medium supplemented with 10 
% FBS (fetal bovine serum) and 1% penicillin/streptomycin was added to the cells. After 24 h 
of incubation at 37°C fluorescence microscopy was used to identify iHUVECs that were 
successfully transfected with pIRES2-EGFP carrying the gene of interest.  According to the 
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manufacturer the EGFP encoded by the plasmid was expected to have its excitation maximum 
at 488 nm and its emission maximum at 507 nm. 
 
Flow cytometry 
Flow cytometry was carried out by the Division of Rheumatology/Department of Internal 
Medicine III in cooperation with the Core Unit Cell Sorting, both from the Medical 
University of Vienna. Flow cytometric cell sorting was performed in order to isolate and 
quantify successfully transfected cells. Cells were harvested 48 h after transfection by 
addition of 1x trypsine/EDTA and immediate centrifugation for 4 min. at 1800 rpm. The 
resulting pellet was resuspended in 1 ml of RPMI 1640 medium supplemented with 10 % 
FBS (fetal bovine serum) and 1% penicillin/streptomycin and 7-amino-actinomycin D (7-
AAD, Fluka, Buchs SG, Switzerland, cat. no. 06648) was added at 1 μg/ml. Flow cytometric 
cell sorting was then carried out using a BD FACSAria™ flow cytometer, EGFP emission 
being detected via FL1 channel using a bandpass filter at 530±15nm. Sort criteria combined a 
generously wide scatterlight region excluding small particles (cell fragments and debris) with 
positivity for EGFP as well as negativity for 7-AAD. Furthermore, transfection efficiencies 
and EGFP half-life were determined using a BD FACSCalibur™ flow cytometer. The sorted 
EGFP-positive, 7-AAD negative cells were lysed in 350μl of RLT buffer supplemented with 
1% β-mercaptoethanol and stored at -80°C until RNA isolation was executed. For isolation of 
sufficient RNA, the sorting had to yield at least 300,000 EGFP-positive cells. 
 
Immunefluorescence staining of HOXA3 proteins 
The purpose of immunefluorescence staining was to analyze the distribution of the HOXA3 
protein in the cell under several conditions including transient expression of the protein to be 
analyzed, overexpression of another protein or normal conditions. Prior to immune 
fluorescence staining iHUVECs maintained RPMI 1640 medium supplemented with 10 % 
FBS (fetal bovine serum) and 1% penicillin/streptomycin were grown in 9.6 cm2 petri dishes. 
On the day of staining the medium was removed and the cells were fixed in 4% PFA in PBS 
for a minimum of 10 min at room temperature. After removal of 4% PFA/PBS the cells were 
washed three times with PBS and 0.1% Triton-X-100 in PBS was added for permeabilization 
of the cell membrane. After 10 min. of incubation at room temperature Triton-X-100 was 
removed and 200 μl of goat serum diluted in PBS at a ratio of 1:10 were added to each 9.6 
cm2 dish for 20 min. in order to block unspecific binding sites. Prior to use, the primary 
antibody (Anti-HOXA3) was diluted in PBS at a ratio of 1:100. The antibody of choice 
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against HOXA3 was the unconjugated polyclonal antibody anti-homeobox protein Hox-A3 
(AVIVA SYSTEMS BIOLOGY; cat. no. ARP36056_T200) produced in rabbits. Anti-Hoxa3 
was delivered in a state lyophilised from PBS buffer with 2% sucrose. After addition of 100 
µl distilled water the final antibody concentration was 2 mg/ml. 
The primary antibody was added to the cells for 45 min. at room temperature. Afterwards, the 
cells were washed with PBS before the secondary antibody diluted in PBS at a ratio of 1:1000 
was added. In case of rabbit anti-human HOXA3 polyclonal antibody serving as primary 
antibody, the secondary antibody of choice was Alexa Fluor 594 goat anti-rabbit antibody 
(MolecularProbes) labelled with red-fluorescent dye. The secondary antibody was added for 
45 min. at room-temperature. After washing with PBS, DAPI-staining (1:50,000) was 
executed for 1 min. in order to visualize cell nuclei. After the final wash step with PBS, cells 
were covered with GelTol mounting medium (Thermo Electron Corporation, PA, USA, cat. 
no. 484950) and a cover glass. Analysis of immunostained cells was performed under the 
microscope. AxioCam (ZEISS, Germany) was used for taking pictures of the cells. 
 
4.6 Protein chemistry methods 
 
Protein assay in Laemmi buffer 
This method was executed according to the article of Karlsson et al. (1994) in order to 
determine protein concentrations within cell samples. At the beginning, cell samples were 
solubilized in Laemmli buffer and heated at 96°C for 3 min. before centrifugation at 10,000 x 
g for 5 min. was performed. Next, 9 μl aliquots of the samples were applied to a microtiter 
plate and diluted at a ratio of 1:10 by addition of 81 μl of Laemmli buffer.  
Different concentrations (500 μg/ml, 250 μg/ml, 100 μg/ml, 50 μg/ml, 25 μg/ml and 10 
μg/ml) of bovine serum albumin (BSA) solubilized in Laemmli buffer were prepared in order 
to determine protein concentrations of the samples by a BSA standard curve. Then, 90 μl of 
the respective BSA solutions were also applied to the microtiter plate.  
Finally, 60 μl of 60% TCA were added to the samples and the BSA solutions and the yellow 
turned mixtures were incubated for 10-30 min. at room temperature. 
Microplate reader Synergy-HT (BIO-TEK) was used for measuring turbidity of the samples 
and the BSA-solutions at 570 nm. Furthermore, a BSA standard curve was built in order to 
determine protein concentrations (μg/ml). In order to obtain correct protein concentrations it 
was necessary to take the dilution of the samples (1:10) into account.  
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Western blot analysis  
Western blots of transfected and nontransfected iHUVECs were probed for HOXA3. Western 
blot analysis of HOXA3 protein was done for CFL1, CASP3 and HOXA3 transfected 
iHUVECs as well as for nontransfected cells. At the beginning 20μg of total protein isolated 
from transfected and nontransfected cells were applied to SDS-PAGE carried out at 120V. 
The running gel used for separation of proteins contained 12% acrylamide. Transfer of 
proteins to nitrocellulose membranes was carried out at 20V overnight. After transfer, the 
nitrocellulose membrane was stained with Ponceau S red in order to visualize proteins. The 
membrane was then blocked with 5% milk powder in 1xTBST for at least 20 min. The 
primary antibody was added at room temperature for 1 h. The antibody of choice against 
HOXA3 was Mouse Anti-Human HOXA3 Polyclonal Antibody, Unconjugated from ABR-
Affinity BioReagents (cat. no. PA1-52660). Prior to use, anti-HOXA3 was diluted at a ratio of 
1:1000 in 2.5% milk powder in 1xTBST. After 1 h of incubation with the primary antibody 
the membrane was washed three times for 5 min. each with1xTBST. The secondary antibody 
(HRP rabbit anti-mouse) diluted at a ratio of 1:4000 in 2.5% milk powder in 1xTBST was 
then added to the blots at room temperature for at least 1 h. Afterwards, several washing steps 
using TBST were carried out for 50 min. Finally, ECL plus™ Western Blotting Detection 
Reagent (Amersham Biosciences) was added to the blot prior to detection of HOXA3 by 
chemiluminescence using Lumi-Imager F1™ (Rocher). Analysis of images acquired by 
Lumi-Imager F1™ was carried out using LumiAnalyst™ software (Rocher). 
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5 Results 
 
5.1 Flow cytometry 
 
Separation and counting of iHUVECs successfully transfected with the cloned coding 
sequence of HOXA3 were executed by flow cytometric cell sorting. Thereby, we collected of 
a total number of 307,423 intact, viable EGFP-positive cells for subsequent isolation of total 
RNA.  
 
5.2 RNA-isolation and Multiplex PCR 
 
Total RNA isolated from iHUVECs transiently expressing HOXA3 was reverse- transcribed 
in order to obtain cDNA that could be applied to quantitative real time PCR. Before cDNA 
was loaded onto TaqMan® Low Density Custom Arrays, multiplex PCR of four housekeeping 
genes (BCR, β2-microglobulin, ABL and PBGD) was performed, providing information 
about quality and integrity of cDNAs produced by reverse transcription. Multiplex PCR 
products separated on a 2 % agarose gel yielded four bands of different size (Figure 6). In 
order to exclude technical failures concerning the method, multiplex PCR was carried out for 
a control sample as well (data not shown).  
 
 
Figure 6. Control of quality and integrity of cDNA sample 
Multiplex PCR of the four housekeeping genes (BCR, β2-microglobulin, ABL and PBGD) 
and subsequent separation of the PCR products by 2 % agarose gel electrophoresis yielded 
four bands (lane 2) of different size (BCR: 377 bp, β2-microglobulin: 287 bp, ABL: 193 bp, 
PBGD: 128 bp). The 100 bp ladder (lanes 1 and 3) was used as size marker. 
 
 1 
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5.3 Quantitative real time PCR 
 
5.3.1 Determination of fold change and correlation in expression patterns 
 
The aim of high throughput real time PCR was to investigate the effects of transient 
expression of the HOXA3 gene on the expression of the 125 candidate genes relevant to 
diabetic microangiopathy. Therefore, cDNA obtained from reverse transcription of total RNA 
isolated from iHUVECs transiently expressing HOXA3 was loaded onto two TaqMan® Low 
Density Custom Arrays (referred to as DMA1 and DMA2). A total of 128 pre-made assays 
were spotted on both micro-fluidic cards enabling 128 simultaneous quantitative real time 
PCR reactions (as already described in Materials and Methods sections).  
Analysis of quantitative real time PCR with SDS 2.2 software generated sigmoid curves 
representing the increase of the respective PCR products. In order to obtain precise Ct values, 
thresholds were set manually within regions of linear increase of these curves. After 
normalization of Ct values to these of GAPDH, the two housekeeping genes NARS and 
TARDBP and the calibrator sample, the fold change was determined according to the 
formula: 
 
FC = 2-ΔCt = xij/xi0  
 
Software developed within our group (Stokic et al., 2008) was able to create four different 
profiles for analysis of functional interactions between members of the candidate gene set as 
well as correlations in expression patterns. On the one hand, this software was used to 
generate global profiles of both, expression and correlation, but on the other hand profiles of 
single gene expression and correlation were created.  
Global profiles of correlation allowed for analysis of correlation between transiently 
expressed genes concerning their effects on the expression of the candidate gene set. 
The global profile of expression was built in order to demonstrate the upregulating and 
downregulating effects of a transiently expressed gene on candidate gene expression. 
The expression pattern of a certain gene within the candidate gene set as a result of the 
respective experiments of transient gene expression was demonstrated by the single gene 
expression profile. The single gene profile of correlation allowed for analysis of correlation 
between all candidate genes within the set concerning their expression as a result of transient 
gene expression. 
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In order to obtain reliable results, three replicates of transient expression of HOXA3 followed 
by RNA-isolation, cDNA synthesis and quantitative real time PCR were executed. 
Transfected iHUVECs of the first trial emerged to be contaminated by mycoplasms whereas 
cells used for transfection during the second and the third trials were free from contamination. 
Since the experimental conditions of the third trial of transient expression of HOXA3 were 
most favourable, data obtained from this trial were considered to be significant for 
examination of the role of HOXA3 in a gene network relevant to diabetic microangiopathy.  
 
1) The global profile of correlation was used to compare the respective effect on the 
candidate gene set of every transiently expressed gene to the effect of transient expression of 
HOXA3 on candidate gene expression (Figure 7). More precisely, the global profile of 
correlation built for HOXA3 allowed for analysis of correlation between transiently expressed 
HOXA3 and the other overexpressed genes in terms of their effects on candidate gene 
expression. Values close to +1 indicated a high degree of correlation whereas values close to 
0 reflected poor correlation. Table 2 outlines correlations that emerged between transient 
HOXA3 expression and overexpression of 44 genes concerning the influence on the candidate 
gene set.  
Concerning the effect on the candidate gene set, HOXA3-new was found to show highest 
correlation with overexpression of RPIB1 (correlation value: 0.864). The RPIB1 gene encodes 
ribose-5-phosphate isomerase, an enzyme that converts ribulose 5-phosphate to ribose-5-
phosphate in the pentose phosphate pathway (Huck et al., 2004).  
Furthermore, transient expression of the gene encoding the intercellular adhesion molecule 
ICAM1 showed high correlation with transiently expressed HOXA3-new in terms of the 
effects on the expression of the candidate gene set (correlation value: 0.738).  
Comparison of the three trials of transient expression of HOXA3 with respect to the influence 
on the expression pattern of the candidate genes delivered interesting results. Correlation 
found between transiently expressed HOXA3 of the second (HOXA3-2.Versuch) and the 
third (HOXA3-new) trial accounted for almost 72% (correlation value: 0.717). Both trials of 
transient HOXA3 expression were carried out under similar conditions using iHUVECs free 
from any contamination. Nevertheless, small differences concerning the effects on candidate 
gene expression between HOXA3-2.versuch and HOXA3- new were detected. This result was 
acceptable however, since small variations concerning gene expression in iHUVECs after two 
trials of transfection with HOXA3 were expected to occur. Comparison of transiently 
expressed HOXA3 of the first trial (HOXA3-old) to HOXA3-new yielded a significant 
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difference in terms of the effects on the candidate gene expression. Cells used for transient 
exogenous expression of HOXA3 in the first trial turned out to be contaminated with 
mycoplasms. Correlation found between HOXA3-old and HOXA3-new accounted for 13% 
(correlation value: 0.131). As expected, this result strongly suggests that mycoplasm 
contamination has significant influence on the gene expression profile of cells affected. 
Concerning the influence on the expression of the candidate gene set, transient expression of 
two more genes was found to yield a correlation value greater than 0.7 when compared to 
HOXA3-new. One of them, UGDH (correlation value: 0.707) encodes the enzyme UDP-
glucose dehydrogenase that is known to catalyze two oxidations of UDP-glucose to generate 
UDP-glucuronic acid required for synthesis of extracellular matrix polysaccharides (Sommer 
et al., 2004). The other one, PLD (correlation value: 0.703) codes for phospholipase D, an 
enzyme that hydrolyzes phosphatidylcholine to yield the lipid second messenger phosphatidic 
acid and free choline (Whatmore et al., 1996).  
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Table 2. Correlations between transient HOXA3 expression and overexpression of 44 
genes concerning the effect on the candidate gene set. 
Position Gene symbol Correlation value Position Gene symbol Correlation value 
1 HOXA3-new 1.000 24 TGFb1 0.378 
2 RPIB1 0.864 25 CXCL12 0.309 
3 ICAM1 0.738 26 GTPBP4 0.295 
4 HOXA3-2.Versuch 0.717 27 RHOJ 0.277 
5 UGDH 0.707 28 TOR3A 0.273 
6 PLD 0.703 29 PHGDH 0.269 
7 GAPDH 0.687 30 CFH 0.191 
8 CXCR4 0.676 31 PRG 0.187 
9 Endothelin1 0.673 32 CALM2 0.186 
10 IFITM 0.668 33 FZD4 0.179 
11 NOS3 0.598 34 IMPA 0.149 
12 GDI2 0.531 35 PRSS23 0.139 
13 SMAD3 0.520 36 HOXA3-old 0.131 
14 CD99 0.509 37 RPL3 0.128 
15 AQP1 0.491 38 CDYL12 0.116 
16 FGF1 0.439 39 CYR61 0.114 
17 SMAD2 0.431 40 KLF6 0.107 
18 TGFb-R2 0.427 41 BTF3 0.097 
19 PKA 0.426 42 RAMP3 0.065 
20 CFL1 0.420 43 CSPG 0.050 
21 GNAS2 0.404 44 ATP6VOD1 -0.030 
22 GCA 0.398 45 CASP3 -0.065 
23 c-Jun 0.395  
The respective genes involved are listed according to their correlation value, starting with 
the highest degree of positive correlation. The gene symbols HOXA3-old, HOXA3-
2.Versuch and HOXA3-new were used in reference to the first, the second and the third 
trial respectively of transient HOXA3 expression followed by RNA-isolation, reverse 
transcription and quantitative real time PCR. 
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Figure 7. Global profile of correlation built for HOXA3. Values close to +1 indicate a high 
degree of correlation whereas values close to 0 reflect poor correlation. 
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2) The global profile of expression was used to analyze the upregulating and downregulating 
effects of transient HOXA3-expression on the expression of the candidate gene set (Figure 8). 
The magnitude of change in candidate gene expression as a result of HOXA3 overexpression 
was displayed by determination of the fold change. Table 3 summarizes the most upregulated 
as well as the most downregulated candidate genes as a result of transient expression of 
HOXA3. 
Transient expression of HOXA3 was found to result in almost 44600 fold elevated levels of 
HOXA3 transcripts. 
The majority of genes notably upregulated upon transient HOXA3 expression were found to 
encode proteins acting in adipocytes or being involved in reorganization of the actin 
cytoskeleton. 
Overexpression of HOXA3 resulted in enormously increased expression of the EBF gene 
encoding the early B-cell factor. Early B-cell factor is a DNA binding protein that activates 
transcription of several B-cell specific genes and plays a critical role in early B-cell 
development (Hagman et al., 1991). Furthermore, the EBF gene product was found to act as 
transcription factor in olfactory neurons (Kudrycki et al., 1993). The EBF gene was also 
shown to be expressed during adipogenesis, a process by which adipocytes are formed 
(Jimenez et al., 2007).  
Expression of sorbin and SH3-domain-containing-1 (SORBS1) gene known to participate in 
insulin signaling in adipocytes and thereby playing a critical role in the regulation of glucose 
uptake (Baumann et al., 2000) was elevated as a result of HOXA3 overexpression. According 
to previous studies, defects in SORBS1 may play a critical role in the pathology of human 
disorders with insulin resistance including the development of obesity and type 2 diabetes 
(Lin et al., 2001). 
The RHOJ gene encoding a member of the family of small Rho GTPases was upregulated 
upon transient HOXA3 expression. Rho GTPases are known to affect actin cytoskeleton 
reorganization by regulation of actin dynamics. Proteins of the Rho family of small GTPases 
switch between an active GTP-bound and an inactive GDP-bound state (Vignal et al., 2003). 
The Rho GTPase encoded by the RHOJ gene has been found to act as an essential regulator of 
the early endocytic pathway (de Toledo et. al, 2003). Furthermore, RHOJ plays a critical role 
in early adipocyte differentiation (Nishizuka et al., 2003). 
Overexpression of HOXA3 was found to result in elevated expression of the EPHA4 gene 
encoding the EPHA4 receptor that belongs to the Eph family of receptor tyrosine kinases. Eph 
receptors and their ligands, the ephrins are known to act in the developing and the mature 
 49
nervous system (Kullander and Klein, 2002) by reorganization of the actin cytoskeleton 
leading to modification of cell shape and movement (Henkemeyer et al., 2003). The EPHA4 
receptor has been shown to affect β1-integrin signaling pathways in neuronal cells by 
inhibiting β1-integrin activity (Bourgin et al., 2008). 
The expression of the NOS3 gene coding for endothelial nitric oxide synthase was found to be 
upregulated as a result of transient HOXA3 expression. Nitric oxide synthases are known to 
catalyze the synthesis of nitric oxide (NO). Formation of nitric oxide results in its diffusion 
into the smooth muscle where it activates soluble guanylate cyclase (sGC), an enzyme 
catalyzing the synthesis of 3’, 5’- cyclic guanosine monophosphate (cGMP) leading to 
smooth muscle relaxation and vasodilation. Nitric oxide derived from NOS3 is thought to be 
the most important regulator of the vascular tone (Alderton, Cooper and Knowles, 2001). 
Transient expression of HOXA3 resulted in elevated expression of the IL-8 gene encoding the 
chemokine interleukin 8. Furthermore, the expression of the gene coding for gap junction 
protein alpha 1 (GJA1) was upregulated as a result of HOXA3 overexpression. 
Among the candidate genes notably downregulated upon transient HOXA3 expression the 
encoded proteins differ to a great extent in terms of function. 
The ITGA1 gene encoding the integrin alpha subunit and the gene Parkinson disease 
(autosomal recessive, early onset) 7, also known as PARK7 were downregulated as a 
consequence of HOXA3 overexpression.  
Overexpression of HOXA3 was found to result in downregulated expression of the VEGF 
gene coding for the vascular endothelial growth factor. Members of the VEGF gene family 
including VEGF have been shown to be critical for growth and differentiation of vascular as 
well as lymphatic endothelial cells (Korpelainen and Alitalo, 1998). VEGF has been found to 
play a crucial role in the early development of the vasculature. Furthermore, VEGF is 
considered to be the major regulator of angiogenesis (Leung et al., 1989). 
Downregulated expression of the PHGDH gene encoding the enzyme 3-phosphoglycerate 
dehydrogenase was found to occur as a result of transient HOXA3 expression. The PHGDH 
gene product catalyzes the conversion of 3-phosphoglycerate into 3-phosphohydroxypyruvate 
during L-serine biosynthesis (Snell, 1986). L-serine is an important precursor for the synthesis 
of proteins, membrane lipids, glycine and D-serine (Snell, 1984). PHGDH deficiency is 
associated with defective L-serine biosynthesis. Furthermore, it has been found that the 
PHGDH gene product and L-serine are crucial for metabolism, development and function of 
the central nervous system (Klomp et al., 2000). 
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The expression of the GAPDH gene encoding the glycolytic enzyme glyceraldehyde-3-
phosphate dehydrogenase was downregulated upon overexpression of HOXA3. The GAPDH 
protein catalyzes the conversion of glyceraldehyde-3-phosphate into 1, 3-diphosphogycerate. 
Overproduction of superoxide O2- induced by hyperglycaemia has been shown to result in 
activation of the enzyme poly (ADP-ribose) polymerase (PARP) which in turn inhibits the 
enzyme GAPDH by poly-ADP ribosylation resulting in accumulation of glycolytic 
metabolites upstream of GAPDH leading to activation of the four biochemical pathways that 
are known to contribute to hyperglycaemia-induced damage (Du et al., 2003). 
The family of FBXO genes encode proteins, all of them possessing a protein motif also 
referred to as the F-box. F-box proteins are known to be components of the SCF ubiquitin-
ligase complexes. The function of F-box proteins within these complexes is to provide a site 
for protein-protein interaction via their F-box motifs (Kipreos and Pagano, 2000). Upon 
transient expression of HOXA3, the expression of the FBXO7 gene was found to be 
downregulated. 
The C1s gene encodes a serine protease that is known to be a subunit of the multimeric C1 
protein complex of the complement system (Arlaud, Colomb and Gagnon, 1987). C1s cleaves 
and activates C4 and C2 resulting in formation of the C3 convertase (Schumaker, Zavodszky 
and Poon, 1987). Downregulated expression of the C1s gene was found to be the consequence 
of HOXA3 overexpression. 
Another gene notably downregulated upon transient expression of HOXA3 was the GCA 
gene encoding the Ca2+ binding protein grancalcin found in neutrophils, monocytes and 
lymphocytes (Boyhan et al., 1991).  
 
Table 3. List of the most upregulated and the most downregulated candidate genes upon 
transient HOXA3 expression. 
Gene symbol Fold change 
upregulation or 
downregulation Gene symbol Fold change 
upregulation or 
downregulation 
EBF 4.86812E+12 upregulation GAPDH 0.005 downregulation 
HOXA3       44566.06 upregulation ITGA1 0.052 downregulation 
SORBS1             18.89 upregulation PARK7 0.098 downregulation 
RHOJ             15.49 upregulation VEGF 0.098 downregulation 
EPHA4             14.01 upregulation PHGDH 0.123 downregulation 
GJA1             13.53 upregulation FBXO7 0.145 downregulation 
IL-8             13.08 upregulation C1S 0.160 downregulation 
NOS3             10.81 upregulation GCA 0.222 downregulation 
The fold change was determined in order to analyze the magnitude of change in candidate 
gene expression as a result of transient HOXA3 expression.  
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Figure 8. Global profile of expression built for HOXA3. Determination of the fold change 
was executed in order to display the magnitude of change in candidate gene expression as a 
result of HOXA3 overexpression. A fold change greater than 1 indicates upregulated 
candidate gene expression. Downregulated candidate gene expression is indicated by a fold 
change smaller than 1. 
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3) The single gene profile of expression of HOXA3 was built in order to analyze the effects 
of transient expression of the candidate genes including HOXA3 on the expression pattern of 
HOXA3 within the candidate gene set (Figure 9). Changes in HOXA3 expression as a result 
of overexpression of the respective candidate genes were displayed by determination of the 
fold change. Table 4 lists the candidate genes that were found to have the most significant 
influence upon transient expression on the expression pattern of HOXA3. 
As previously described, transient expression of HOXA3 was found to result in elevated 
transcription of HOXA3.  
Transient expression of CFL1 encoding the protein cofilin1 resulted in enormously increased 
expression of endogenous HOXA3. Cofilin1 belongs to the family of actin depolymerising 
factor (ADF)/cofilins. Members of this family are actin binding proteins that are known to 
promote depolymerization of actin filaments, thereby playing a critical role in cytokinesis, 
cell motility and morphogenesis in mammals. The proteins cofilin1 and ADF are coexpressed 
in nonmuscle cells where they contribute to cytoskeletal dynamics with overlapping functions 
(Hotulainen et al., 2005).  
Endogenous HOXA3 expression was elevated as a result of transient KLF6 expression. The 
protein encoded by KLF6 is the Krüppel-like factor 6, a member of the Krüppel-like family of 
transcription factors. Proteins of this family possess highly conserved carboxy terminal zinc 
finger domains enabling specific DNA binding to GC rich sites within the promoter region of 
target genes. The transcription activation domain is located at the amino terminus (Dang, 
Pevsner and Yang, 2000). KLF6 has been found to act as tumor suppressor gene that is 
mutated in human prostate cancer (Narla et al., 2001). Furthermore, KLF6 has turned out to 
promote adipocyte differentiation by inhibition of the proto-oncogene Delta-like1 (DLK1) in 
preadipocytes (Dan Li et al., 2005). 
Another gene found to result in increased expression of endogenous HOXA3 upon transient 
expression was CXCL12 encoding the chemokine that is also referred to as the stromal cell-
derived factor 1. The gene product of CXCL12 has been shown to promote angiogenesis by 
mediating recruitment and migration of endothelial progenitor cells as well as endothelial 
cells in response to ischemic injuries. Binding of the CXCL12 protein to the CXCR4-receptor 
induces the proangiogenic signaling pathway (Askari et al., 2003; Deshane et al., 2007). An 
angiogenesis promoting activity by induction of endothelial cell migration has been also 
demonstrated for HOXA3. Studies revealed that constitutive expression of HOXA3 
accelerated the healing process of diabetic wounds in mice (Kimberly et al., 2005). 
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HOXA3 expression was downregulated upon transient expression of CASP3 coding for 
caspase 3. Caspases are cysteine-aspartyl specific proteases that are known to be crucial for 
apoptosis (Creagh, Conroy and Martin, 2003). Caspase3 is an effector caspase that has been 
found to mediate apoptosis of β-cells of the pancreas, a process known to be significant for 
the occurrence of type 1 diabetes (Liadis et al., 2005). 
Downregulated expression of endogenous HOXA3 was found to occur in untransfected cells 
treated with medium containing high concentrations of D-glucose. Since elevated expression 
of HOXA3 protein has been found in sera of patients suffering from diabetes mellitus (Wick 
et al., unpublished data), this result was unexpected. 
Transient expression of FZD4 encoding frizzled homolog 4 resulted in downregulated 
expression of HOXA3. FZD4 belongs to the frizzled gene family whose members are known 
to code for transmembrane proteins acting as receptors for Wnt ligands (Reya and Clevers, 
2005). The gene product encoded by FZD4 has been found to bind the non-Wnt ligand norrin 
(Nichrs, 2004) that appears to have an angiogenesis promoting activity (Ohlmann et al., 
2005). Studies have revealed that mutations in the FZD4 gene result in familial exudative 
vitreoretinopathy (FEVR), a disorder characterized by defects in retinal vascular development 
(Robitaille et al., 2002). 
Furthermore, downregulated expression of HOXA3 occurred as a result of transient 
expression of ATP6VOD1, a gene encoding the D1 subunit of the transmembrane VO domain 
of the enzyme ATPase. 
 
Table 4. List of the candidate genes having the most significant influence upon transient 
expression on HOXA3 expression within the candidate gene set. 
Gene symbol Fold change 
upregulation or 
downregulation Gene symbol Fold change 
upregulation or 
downregulation 
HOXA3       44566.06 upregulation CASP3             0.002 downregulation 
CFL1       10177.78 upregulation D-glucose             0.079 downregulation 
KLF6             16.87 upregulation FZD4             0.188 downregulation 
CXCL12             12.36 upregulation ATP6VOD1             0.374 downregulation 
Determination of the fold change was performed in order to indicate the magnitude of 
change in HOXA3 expression as a result of transient expression of the respective 
candidate genes including HOXA3. The gene symbol D-glucose refers to untransfected 
iHUVECs that were treated with D-glucose. 
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Figure 9. Single gene profile of expression built for HOXA3. Determination of the fold 
change was executed in order to display the magnitude of change of HOXA3 RNA expression 
as a result of transient expression of the respective candidate genes. A fold change greater 
than 1 indicates upregulated HOXA3 expression. Downregulated HOXA3 expression is 
indicated by a fold change smaller than 1. 
 55
4) The single gene profile of correlation built for HOXA3 allowed for analysis of correlation 
between HOXA3 and all the other candidate genes within the set concerning their expression 
as a result of transient candidate gene expression (Figure 10). Values close to +1 indicated 
high correlation in expression. On the other hand values close to 0 indicated poor correlation. 
Table 5 lists genes that were found to show highest correlation with HOXA3 concerning their 
expression upon transient expression of the respective candidate genes.  
Values found for correlation between HOXA3 and the other candidate genes concerning their 
expression pattern as a result of transient expression of the respective candidate genes were 
smaller than 0.5. These data indicate correlation below 50% between HOXA3 and the other 
genes within the set in terms of expression in response to the overexpression experiments. 
The gene SERPINE1 encoding the plasminogen activator inhibitor 1, a serine proteinase 
inhibitor protein was found to show highest correlation (correlation value: 0.468) with 
HOXA3 in terms of expression upon overexpression of the respective candidate genes. 
Plasminogen activator inhibitor 1 (PAI-1) has been found to cause detachment of cells from 
extracellular matrices by binding to urokinase plasminogen activator (uPA) in complexes 
mediating attachment of cells to the extracellular matrix. These complexes are composed of 
uPA, its receptor uPAR and integrins (Czekay et al., 2003). Previous studies have revealed a 
link between uPAR and HOXA3 since constitutive expression of HOXA3 leads to 
upregulated expression of uPAR in HMEC-1, an immortalized human dermal microvascular 
endothelial cell line (Kimberly et al., 2005).   
GJA1 coding for the gap junction protein alpha 1 and found to be upregulated upon transient 
HOXA3 expression showed 46% correlation (correlation value: 0.464) with HOXA3 
concerning the expression in response to the overexpression experiments. 
Correlation found between HOXA3 and SMAD3 in terms of expression upon transient 
candidate gene expression accounted for 45% (correlation value: 0.453). The SMAD3 gene 
encodes a protein that belongs to the R-Smads or receptor regulated Smads. TGF-β signaling 
leads to activation of the SMAD3 protein by phosphorylation followed by  
heterodimerization with the SMAD4 protein. These heterodimers translocate to the nucleus 
where they regulate target gene transcription (Heldin, Miyazono and Dijke, 1997). 
Correlation accounting for 42% was found between HOXA3 and CASP3 (correlation value: 
0.429) in terms of expression in response to the overexpression experiments. CASP3 coding 
for an effector caspase was already shown to result in downregulated expression of HOXA3 
upon transient expression of the CASP3 gene. 
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Genes found to show correlation of 40% with HOXA3 concerning their expression upon 
overexpression of the candidate genes were EPHA4 (correlation value: 0.406), PRSS23 
(correlation value: 0.404) and IL-8 (correlation value: 0.396).  
EPHA encoding the EPHA4 receptor, a member of the Eph family of receptor tyrosine 
kinases was already found to be upregulated upon transient HOXA3 expression. 
PRSS23, also known as protease serine 23 encodes a serine protease that has been found to 
act as critical ovarian protease in vertebrates (Miyakoshi et al., 2006). 
IL-8 coding for the chemokine interleukin 8 was also found to be upregulated as a result of 
transient HOXA3 expression. 
 
Table 5. List of genes found to show highest correlation with HOXA3 concerning their 
expression as a result of transient candidate gene expression. 
Position Gene symbol Correlation value Position Gene symbol Correlation value 
1 HOXA3 1.000 5 CASP3 0.429 
2 SERPINE1 0.468 6 EPHA4 0.406 
3 GJA1 0.464 7 PRSS23 0.404 
4 SMAD3 0.453 8 IL-8 0.396 
The respective genes are listed according to their correlation value, starting with the 
highest degree of correlation. 
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Figure 10. Single gene profile of correlation built for HOXA3. Values close to +1 
indicated high correlation in expression whereas values close to 0 indicated poor correlation. 
Values found for correlation between HOXA3 and the other candidate genes in terms of 
expression in response to the overexpression experiments were smaller than 0.5.  
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5.4 HOXA3 in a gene network relevant to diabetic microangiopathy 
 
In the course of the project aiming at identification of a gene network relevant to diabetic 
microangiopathy, a total of 37 candidate genes including HOXA3 were cloned into the 
expression vector pIRES2-EGFP and transiently expressed in iHUVECs prior to RNA-
isolation from successfully transfected cells, reverse transcription and quantitative real 
time PCR of cDNA samples. Determination of the fold change was executed to analyze 
the effects of transient expression of a certain gene on the expression of the candidate 
gene set as it was shown in global and single gene profiles of both, expression and 
correlation without revealing direct or indirect regulatory interactions. In order to build a 
gene network represented by the adjacency matrix A, it was necessary to identify all the 
direct functional links between the candidate genes according to the formula: 
 
A = ln (D+I) 
 
On the basis of regulatory interactions found between transiently expressed candidate 
genes (see appendix), it was possible to create a network comprising 37 genes (Figure 
11), which was assumed to be of relevance to diabetic microangiopathy. This network 
demonstrated the most significant functional links between genes that might play a 
critical role in the occurrence of diabetic microvascular complications. The relative 
position of each gene within this network was determined according to the number of 
functional links between the respective gene and other genes. Functional links found 
between genes constituting the network represented activating or inhibitory effects. In 
addition, significant effects of the respective genes on their own expression were also 
demonstrated in this gene network relevant to diabetic microangiopathy. In order to be 
incorporated into the gene network, interactions between the candidate genes had to be 
greater than a certain threshold in terms of strength. 
Table 6 describes the strength of direct functional links of HOXA3 to all the other 
candidate genes that were transiently expressed in the course of the project. The genes 
CFL1 and CASP3 were identified to be significantly involved in regulatory interactions 
with HOXA3. CFL1 encoding the protein cofilin1 was found to have an upregulating 
effect on the expression of HOXA3, whereas CASP3 coding for an effector caspase was 
described to have a downregulating effect on HOXA3 expression. Furthermore, a notable 
activating effect of HOXA3 on its own expression was demonstrated. Further significant 
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interactions of HOXA3 with candidate genes transiently expressed were not identified. 
Therefore, HOXA3 was found to take a peripheral position in the gene network, where its 
functional links to CFL1 and CASP3 as well as the activating effect on its own 
expression were demonstrated.  
 
Table 6. Summary of direct interactions found between HOXA3 and all the other 
transiently expressed candidate genes. 
from to 
strenght of 
interaction effect from to 
strenght of 
interaction effect 
CFL1 HOXA3 3.861057 upregulation HOXA3 FZD4 0.239946 no effect
CASP3 HOXA3 -3.037106 downregulation FGF1 HOXA3 0.239667 no effect
HOXA3 HOXA3 2.284825 upregulation  HOXA3 CFL1 0.238254 no effect
Endothelin1 HOXA3 -1.073105 no effect HOXA3 KLF6 0.232501 no effect
CALM2 HOXA3 -0.977092 no effect BTF3 HOXA3 -0.226815 no effect
PLD HOXA3 -0.969137 no effect RPIB9 HOXA3 0.219708 no effect
TGFb-R2 HOXA3 0.742079 no effect HOXA3 RAMP3 -0.206556 no effect
PRSS23 HOXA3 0.740413 no effect HOXA3 FGF1 0.203323 no effect
TGFb1 HOXA3 0.735693 no effect RAMP3 HOXA3 0.183082 no effect
HOXA3 GAPDH -0.721046 no effect HOXA3 UGDH 0.166775 no effect
GTPBP4 HOXA3 0.644008 no effect HOXA3 BTF3 -0.147050 no effect
TOR3A HOXA3 0.612508 no effect HOXA3 CASP3 0.129217 no effect
CFH HOXA3 0.571996 no effect ATP6VOD1 HOXA3 0.122829 no effect
FZD4 HOXA3 0.545993 no effect HOXA3 TOR3A -0.122777 no effect
HOXA3 PRSS23 0.526719 no effect HOXA3 CSPG -0.120706 no effect
HOXA3 AQP1 -0.494100 no effect HOXA3 SMAD2 -0.116524 no effect
RHOJ HOXA3 0.486262 no effect HOXA3 TGFb1 0.116499 no effect
KLF6 HOXA3 0.469992 no effect c-JUN HOXA3 0.109867 no effect
HOXA3 RPIB9 -0.458962 no effect HOXA3 CDYL12 -0.109686 no effect
GCA HOXA3 0.457223 no effect UGDH HOXA3 0.106492 no effect
HOXA3 SMAD3 0.426192 no effect CSPG HOXA3 0.071653 no effect
SMAD2 HOXA3 0.417238 no effect HOXA3 Endothelin1 0.069464 no effect
HOXA3 PLD -0.411843 no effect AQP1 HOXA3 0.068006 no effect
GAPDH HOXA3 0.385663 no effect HOXA3 GCA 0.066035 no effect
PHGDH HOXA3 0.367620 no effect CYR61 HOXA3 -0.064949 no effect
HOXA3 c-JUN 0.347007 no effect HOXA3 ATP6VOD1 0.061754 no effect
ICAM1 HOXA3 0.337033 no effect HOXA3 ICAM1 -0.057733 no effect
GNAS2 HOXA3 -0.329482 no effect HOXA3 CFH 0.052311 no effect
SMAD3 HOXA3 0.324979 no effect HOXA3 GTPBP4 -0.042365 no effect
HOXA3 NOS3 0.317200 no effect CXCL12 HOXA3 0.041873 no effect
HOXA3 CXCL12 0.299946 no effect HOXA3 GDI2 -0.039585 no effect
GDI2 HOXA3 -0.293912 no effect HOXA3 TGFb-R2 0.028100 no effect
HOXA3 RHOJ 0.284675 no effect HOXA3 PRG -0.015214 no effect
HOXA3 CYR61 0.277071 no effect NOS3 HOXA3 -0.011407 no effect
CDYL12 HOXA3 0.268072 no effect HOXA3 GNAS2 -0.008812 no effect
HOXA3 PHGDH -0.255345 no effect HOXA3 CALM2 -0.003165 no effect
PRG HOXA3 0.242248 no effect    
Only the most significant functional links of HOXA3 to other genes were incorporated 
into the gene network composed of 37 genes. Positive values greater than a certain 
threshold of 1.334 were considered to indicate activating effects whereas negative values 
smaller than a threshold of -1.130 were thought to reflect inhibitory effects.  
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Figure 11. HOXA3 in a gene network of possible relevance for diabetic 
microangiopathy. HOXA3 takes a peripheral position in the gene network since there is 
a smaller number of significant functional links between HOXA3 and the other genes 
involved. In this network, HOXA3 expression is demonstrated to be activated by CFL1 
and inhibited by CASP3. Furthermore, an activating effect of HOXA3 on its own 
expression is demonstrated. In this illustration of the gene network, arrows indicate the 
direction of regulatory action. Upregulating effects are illustrated by continuous lines 
between interacting genes, Downregulating effects are indicated by discontinuous lines 
between interacting genes. 
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5.5 Western blot analysis and immunofluorescence staining of HOXA3  
 
As mentioned above HOXA3 was found to be functionally linked to the genes CFL1 and 
CASP3 in a network that comprises 37 genes and is assumed to be of relevance to 
diabetic microangiopathy. Furthermore, a significant positive effect of HOXA3 on its 
own expression was identified. In order to verify these findings, Western blot analysis 
and immunofluorescence staining of HOXA3 protein were carried out comparing 
iHUVECs transiently expressing HOXA3, CFL1 and CASP3, respectively, to 
untransfected cells. 
 
5.5.1 Western blot analysis of HOXA3 protein 
 
Western blot analysis of HOXA3 protein was done using cell lysates of untransfected and 
transfected iHUVECs, where transfected cells were transiently expressing HOXA3 or 
CFL1 or CASP3. When compared to untransfected iHUVECs elevated expression of 
HOXA3 protein was detected upon transient expression of HOXA3 and CFL1 (Figure 
12). A downregulating effect of CASP3 on HOXA3 expression as it was demonstrated in 
the gene network was not confirmed since overexpression of CASP3 was not found to 
result in decreased levels of HOXA3 protein. 
 
 
 
           
 
                        
Figure 12. Western blot analysis of HOXA3 expression in transfected and 
untransfected iHUVECs. HOXA3 expression is shown as a result of transient 
expression of CFL1 (lane 1) CASP3 (lane 2) and HOXA3 (lane3). When 
compared to untransfected iHUVECs (lane 4), HOXA3 expression was found to 
be upregulated upon transient expression of CFL1 and HOXA3. Note that 
overexpression of CASP3 did not result in downregulated expression of HOXA3. 
 
 
 
 
 
CFL1 CASP3 HOXA3 Untransfected iHUVECs 
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5.5.2 Immunofluorescence staining of HOXA3 protein 
 
Cells successfully transfected with expression vector pIRES2-EGFP carrying the 
respective gene of interest showed a green signal as a result of EGFP expression.  
When compared to untransfected cells (Figure 4d) immunofluorescence staining of 
protein encoded by HOXA3 in iHUVECs transiently expressing CFL1 (Figures 4a-1, 4a-
2) revealed increased concentrations of HOXA3 protein in the cytoplasm and in the 
nucleus confirming the upregulating effect of CFL1 on the expression of HOXA3 as it 
was demonstrated in the gene network relevant to diabetic microangiopathy. 
Elevated levels of HOXA3 protein were also found in iHUVECs transiently expressing 
HOXA3 (Figures 4b-1, 4b-2). In these cells especially the nucleus showed high 
concentrations of HOXA3 protein. 
In contrast to Western blot analysis, immunofluorescence staining of HOXA3 protein 
was found to demonstrate a downregulating effect of CASP3 on HOXA3. When 
compared to untransfected cells decreased levels of HOXA3 protein were found in the 
cytoplasms and in the nuclei of iHUVECs transiently expressing CASP3 (Figures 4c-1, 
4c-2). 
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Figure 4. Immunofluorescence staining of HOXA3 protein.  
The concentrations of HOXA3 protein in the cytoplasms and in the nuclei of iHUVECs 
transiently expressing CFL1 (a-1, a-2) or HOXA3 (b-1, b-2) or CASP3 (c-1, c-2) were 
compared to the levels of HOXA3 protein in untransfected cells (d). On the left side 
single channel images of iHUVECs in red show the cellular distribution of HOXA3 
protein represented by the red signal. Images of the same cells on the right side 
additionally depict in green the result of EGFP expression, indicating successful 
transfection with expression vector pIRES2-EGFP carrying the respective gene of 
interest. Cells transiently expressing CFL1 were found to have elevated levels of HOXA3 
protein in the cytoplasm and in the nucleus. Increased concentrations of HOXA3 protein 
were detected in the nuclei of iHUVECs transiently expressing HOXA3. Decreased 
levels of HOXA3 protein were found in the cytoplasms and in the nuclei of cells 
overexpressing the CASP3 gene.  
a-1 
b-1 
c-1 
d 
a-2 
b-2 
c-2 
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6 Discussion 
 
The idea of creating a gene network for diabetic microangiopathy was to demonstrate the 
interactions of functional relevance between candidate genes assumed to control the 
occurrence and course of microvascular complications. We could build a network composed 
of 37 candidate genes that had previously been identified in an ex vivo screen for transcripts 
regulated in BECs of diabetic versus non-diabetic capillaries. The position of each gene was 
determined by the number of its functional links to other genes involved and thereby provided 
information about the possible role of a gene in microvascular complications. Genes taking a 
central position within the network were considered to be key players in the occurrence of 
diabetic microangiopathy since they had a higher number of functional links than genes 
occupying a peripheral position.  
Initially, a total of 125 candidate genes hypothesized to control microvascular complications 
was identified by gene expression profiling comparing (i) blood vascular endothelial cells 
(BECs) derived from tissue samples of diabetic and non-diabetic patients and (ii) BECs 
cultured in vitro under diabetic conditions, as well as by (iii) literature search. However, the 
fact that our final gene network was built from only 37 of these 125 identified candidate genes 
gives rise to doubts concerning the biological relevance of the network. The major point of 
criticism is that some important gene regulatory interactions may remain obscured as a result 
of the small number of genes constituting the network. Thus, it is unlikely that the regulatory 
interactions identified between the 37 genes within our network suffice to understand the 
whole process of gene regulation contributing to diabetic microangiopathy. However, this 
gene network can be considered as an important step to reveal the secrets of gene regulatory 
interactions controlling the occurrence of microvascular complications.  
One reason for restricting the final gene network to barely 30 % of all identified candidate 
genes was the time consuming biological methods to obtain the data required for gene 
network construction. Each of the candidate genes had to be cloned into the expression vector 
pIRES2-EGFP and be transiently expressed in iHUVECs. Successfully transfected cells were 
sorted by flow cytometry which had to yield at least 300,000 enhanced green fluorescent 
protein (EGFP) -positive cells for subsequent RNA-isolation. Isolated RNA was reverse 
transcribed and the resulting cDNA-sample was subjected to quantitative real time PCR, 
which was expected to deliver data essential for the construction of our gene network. 
Sometimes technical difficulties were found to delay the progression of the project. For 
example, for some of the candidate genes several unsuccessful attempts of cloning had to be 
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overcome, which were the result of problems occurring during PCR amplification or failure in 
restriction enzyme digestion.  
 
As already mentioned, the candidate genes were cloned into pIRES2-EGFP prior to transient 
transfection of iHUVECs. The reason for choosing this expression vector was the highly 
efficient detection of successfully transfected cells by flow cytometric cell sorting. The 
characteristic of pIRES2-EGFP is the presence of an internal ribosomal entry site (IRES) 
located between the multiple cloning site and the coding region of the EGFP. The 
consequence of this construction is translation of the gene that is cloned into the multiple 
cloning site and the EGFP gene from a single bicistronic mRNA.  
Although diabetic microangiopathy seems to be the consequence of altered gene expression 
over a long period of time, the short duration of downstream effects upon transient candidate 
gene expression was considered appropriate to study the role of the respective candidate genes 
in the microvascular complications. This decision was a consequence of the fact that stable 
transfections of iHUVECs in order to analyze the long-term effects of permanent 
overexpression of the candidate genes on the gene expression patterns of endothelial cells 
would have meant unrealistically great expenditure of time.  
Human umbilical vein endothelial cells (HUVECs) immortalized with the human telomerase 
catalytic protein (hTERT) were used for our transfection experiments. These cells were shown 
to largely maintain their endothelial character and therefore making them appropriate for the 
studies of diabetic microangiopathy (Aurea Burchard, personal communication). Moreover, 
iHUVECs could be transfected at a reasonably high efficiency of up to 75 % with pIRES2-
EGFP; which was in contrast to much lower results when using microvascular BECs. Still, the 
origin of iHUVECs from the umbilical vein that normally is not subjected to diabetic 
complications is a drawback worth to mention. However, in principal we tested gene 
interactions that should be found in any condition, if gene products were of appropriate 
relative levels, i.e. not necessarily diabetes-specific. Thus, the iHUVECs seemed to be a good 
compromise between technical feasibility and biological representativity. 
Quantitative real time PCR was the method of choice in order to detect changes in candidate 
gene transcripton upon transient gene expression in iHUVECs. An alternative approach for 
measurement of changes in expression levels could have been the use of DNA chips. 
However, the higher costs of DNA chips as well as the lower accuracy and lower sensitivity 
of hybridization were the reason for choosing quantitative real time PCR for analysis of 
candidate gene transcription in response to the overexpression experiments. Moroever, from 
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the bioinformatical point of view quantitative real time PCR was more favorable for gene 
network construction than DNA chips, since this approach was expected to deliver more bits 
of information per data point than DNA chips. Thus, fewer data points were required in case 
of using real time PCR to accomplish the same accuracy when working with DNA chips 
(D’haeseleer et al., 2000). 
 
In this diploma thesis a peripheral position of the HOXA3 gene within our 37 genes 
comprising network is reported. According to the gene network HOXA3 expression was 
directly regulated by the genes CFL1 and CASP3. Furthermore, an activating effect of 
HOXA3 on its own expression was suggested. CFL1 encoding cofilin1 that is known to 
contribute to cytoskeletal dynamics in nonmuscle cells (Hotulainen et al., 2005) activated 
HOXA3 expression. On the other hand, CASP3 coding for caspase 3, an effector caspase 
mediating apoptosis of pancreatic β-cells (Liadis et al., 2005), seemed to have a 
downregulating effect on the expression of the HOXA3 gene. In order to verify these findings 
Western blot analysis and immunofluorescence staining of HOXA3 protein were carried out. 
Both approaches involved transient transfection of iHUVECs with pIRES2-EGFP carrying 
the coding sequence of the gene suggested to regulate the expression of HOXA3. The levels 
of HOXA3 protein detected in cells transiently expressing CFL1, CASP3 and HOXA3, 
respectively, were compared to endogenous HOXA3 expression in untransfected cells. 
Western blot analysis and immunofluorescence staining of HOXA3 protein were not carried 
out for iHUVECs transiently transfected with empty pIRES2-EGFP However, an empty 
vector control would have been reasonable for two reasons: First, initial determination of the 
fold change in gene expression was executed by comparison of Ct values obtained from 
quantitative real time PCR to those of a calibrator sample which was derived from iHUVECs 
transfected with empty pIRES2-EGFP. Second, effects of plasmid backbone on gene 
expression cannot be excluded. However, according to the single gene profile of HOXA3, no 
significant differences to untransfected cells treated with RPMI medium containing L-glucose 
were found to occur in terms of HOXA3 expression. Therefore, we still feel to be able to 
interpret correctly the possible role of HOXA3 within the gene network. 
Specifically, three different experiments were carried out: 
First, not unexpected, transient HOXA3 expression was also found to result in elevated levels 
of HOXA3 protein. On the one hand these higher amounts of HOXA3 protein could be the 
result of the additional exogenous expression of HOXA3 without any effect on the expression 
of endogenous HOXA3. On the other hand an autoinducive effect of HOXA3 on its own 
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expression could be the reason for the elevated levels of HOXA3 protein in cells transiently 
expressing HOXA3.  
Second, Western blot and immunofluorescence analyses revealed activated HOXA3 
expression in iHUVECs transiently expressing CFL1 when compared to untransfected cells. 
Third, Western blot analysis and immunofluorescence staining of iHUVECs transiently 
expressing CASP3 delivered different results concerning the effect on HOXA3 expression. 
Western blot analysis of cells transiently expressing CASP3 revealed levels of HOXA3 
protein equal to those in untransfected cells. This unexpected result may be explained by the 
fact that cells used in these confirmation experiments were not subjected to flow cytometric 
cell sorting after transfection and therefore it is likely that a great amount of these iHUVECs 
assumed to be successfully transfected did not contain the expression vector carrying the 
CASP3 gene. On contrary, microscopic inspection of cells transiently expressing the CASP3 
gene after immunofluorescence staining of HOXA3 protein revealed downregulated HOXA3 
expression, when compared to untransfected iHUVECs. This latter result seems more 
significant, since the green signal of the EGFP protein detected in analyzed iHUVECs 
allowed identification of cells that were successfully transfected with pIRES2-EGFP carrying 
CASP3 coding sequence and exclusion of negative ones. 
 
Three trials of transient HOXA3 expression followed by RNA-isolation, reverse transcription 
and quantitative real time PCR were compared with respect to the effects on candidate gene 
expression. Cells transiently transfected in the first trial were contaminated with mycoplasms, 
whereas iHUVECs used in the other two trials were free from contamination. Considerable 
differences in candidate gene expression between contaminated and non-contaminated cells 
were observed upon transient transfection with pIRES2-EGFP carrying HOXA3 coding 
sequence. Small variations concerning the effect on the candidate gene set were found even 
between the second and the third trial of transient HOXA3 expression. These findings 
demonstrated the sensitivity of a cell line in terms of gene expression. However, these small 
variations between the second and the third trial of HOXA3 overexpression were found in 
expression of those candidate genes that were only slightly affected by transient expression of 
HOXA3. 
 
Besides of the three interactions of HOXA3 with other proteins within the gene network, 
analysis of the effects of transient expression of HOXA3 on the 125 candidate gene set 
delivered interesting results. HOXA3 overexpression was found to result in activated 
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expression of genes encoding proteins that act in adipocytes. Adipocytes are known to serve 
as energy reservoirs by storing free fatty acids. Furthermore, these cells have been found to be 
of broader importance for health. Studies have revealed that adipocytes release various 
proteins that are critical for the regulation of metabolism. For example, enlarged adipocytes of 
obese individuals promote insulin resistance by production of proinflammatory factors and 
increased recruitment of macrophages (Greenberg and Obin, 2006). The expression of the 
genes EBF, SORBS1 and RHOJ was notably upregulated as a result of transient HOXA3 
expression. The Rho GTPase encoded by the RHOJ gene is known to play a critical role in 
early adipocyte differentiation (Nishizuka et al., 2003). The EBF gene encoding the early B-
cell factor has been shown to be expressed during adipogenesis, the process by which 
adipocytes are formed from preadipocytes (Jimenez et al., 2007). Studies have revealed a 
critical role of the SORBS1 gene in the regulation of glucose uptake by participating in 
insulin signaling in adipocytes (Baumann et al., 2000). The finding that HOXA3 activates the 
expression of genes regulating adipogenesis or being involved in insulin signaling in 
adipocytes suggests an important role of HOXA3 in the regulation of these processes.  
Furthermore, HOXA3 might be involved in reorganization of the actin cytoskeleton since 
transient expression of HOXA3 was found to result in activated expression of the genes  
RHOJ (Vignal et al., 2003) and EPHA4 (Henkemeyer et al., 2003) which are known to 
regulate actin dynamics. 
Vice versa HOXA3 was also found to be positively regulated by genes acting in adipocytes 
and contributing to actin dynamics, respectively, indicating that HOXA3 seems to be 
embedded in the regulation of these processes. Within the candidate gene set HOXA3 
expression was notably elevated upon overexpression of CFL1 and KLF6 respectively. As 
already mentioned, CFL1 encoding cofilin 1 plays an important role in the regulation of 
cytoskeletal dynamics in nonmuscle cells (Hotulainen et al., 2005). KLF6 coding for 
transcription factor Krüppel-like factor 6 has been found to inhibit the proto-oncogene Delta-
like1 (DLK1) in preadipocytes and thereby promoting adipocyte differentiation (Dan Li et al., 
2005). 
Previous studies revealed an angiogenesis promoting activity of HOXA3 by induction of 
endothelial cell migration. Constitutive expression of HOXA3 was found to accelerate the 
healing process of diabetic wounds in mice (Kimberly et al., 2005). These findings are 
supported by the activating effect of transiently expressed CXCL12 on endogenous HOXA 
expression as it was found in this diploma thesis. CXCL12 encoding the chemokine that is 
also known as stromal cell-derived factor 1 has been shown to mediate recruitment and 
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migration of endothelial progenitor cells as well as endothelial cells in response to ischemic 
injuries and thereby promoting angiogenesis. The proangiogenic signaling pathway is induced 
by binding of the CXCL12 protein to the CXCR4-receptor (Askari et al., 2003; Deshane et 
al., 2007). 
 
In this diploma thesis, functional links of HOXA3 to the genes CFL1 and CASP3 within a 37 
gene comprising network created by interdisciplinary cooperation between physicists, 
physicians and biologists were suggested.  
In addition, a potential role of HOXA3 in biological processes including adipocyte 
differentiation and insulin signaling in adipocytes as well as reorganization of the actin 
cytoskeleton was found. Beside its function in embryonic development HOXA3 was known 
to be involved in angiogenesis and wound repair so far. Therefore, the results presented in this 
diploma thesis might open new perspectives concerning the function of HOXA3 in diabetic 
microangiopathy that could be analyzed in further studies.  
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Appendix 
 
 
Table 7. Interactions between all candidate genes transiently expressed in the course of 
the project aiming at identification of a gene network in diabetic microangiopathy. 
Position from to Strength of interaction Position from to 
Strength of 
interaction 
1 BTF3 CXCL12 8.242679 41 CASP3 PRSS23 2.727602 
2 PRSS23 RPIB9 7.857261 42 AQP1 AQP1 2.722051 
3 CASP3 ICAM1 -7.712362 43 CFH GAPDH -2.719102 
4 CASP3 SMAD2 -6.414143 44 CASP3 NOS3 2.708902 
5 PRG RPIB9 6.210309 45 CFL1 GAPDH 2.696649 
6 CASP3 PRG -5.738937 46 CFL1 Endothelin1 -2.678154 
7 ATP6V0D1 CXCL12 5.265143 47 PRG CXCL12 -2.66132 
8 CALM2 GAPDH -4.815197 48 CASP3 AQP1 -2.656819 
9 CALM2 RPIB9 4.66573 49 CFL1 PRSS23 -2.629604 
10 CFL1 PLD 4.656133 50 PRG Endothelin1 2.617896 
11 CALM2 PLD -4.478745 51 CASP3 RHOJ 2.60178 
12 CASP3 CASP3 -3.999093 52 PRG FGF1 -2.585011 
13 CFL1 HOXA3 3.861057 53 KLF6 GAPDH 2.549512 
14 CALM2 Endothelin1 3.835349 54 PRSS23 FGF1 -2.538473 
15 CFL1 FGF1 3.782886 55 FGF1 FGF1 2.515363 
16 CALM2 CALM2 -3.732761 56 RHOJ RHOJ 2.49185 
17 CSPG CSPG 3.731625 57 RPIB9 CXCL12 2.479657 
18 BTF3 AQP1 -3.652131 58 CFL1 RAMP3 2.458638 
19 RAMP3 RAMP3 3.575295 59 CFL1 CXCL12 2.419278 
20 PRSS23 CXCL12 -3.413204 60 CYR61 CFH 2.369235 
21 CFL1 PRG 3.395434 61 CFL1 CSPG -2.344377 
22 BTF3 CSPG 3.306348 62 SMAD3 SMAD3 2.33675 
23 ATP6V0D1 GAPDH -3.279249 63 CALM2 NOS3 2.3354 
24 CFL1 CYR61 -3.263373 64 CYR61 RPIB9 -2.333872 
25 CALM2 CYR61 3.233838 65 ATP6V0D1 ATP6V0D1 2.325257 
26 BTF3 RPIB9 3.182712 66 CFL1 c-Jun -2.3076 
27 CALM2 FGF1 -3.181601 67 GNAS2 RPIB9 -2.293562 
28 CASP3 CFH 3.117886 68 HOXA3 HOXA3 2.284825 
29 ATP6V0D1 AQP1 -3.08974 69 CFL1 GCA -2.242516 
30 CFL1 CFL1 -3.081079 70 CALM2 RAMP3 -2.231726 
31 CASP3 CXCL12 3.062254 71 GNAS2 RAMP3 2.226801 
32 CALM2 AQP1 -3.046736 72 CYR61 CSPG -2.217062 
33 CASP3 HOXA3 -3.037106 73 CYR61 GAPDH 2.192965 
34 CALM2 PRSS23 3.02272 74 GNAS2 GNAS2 2.187287 
35 CYR61 RAMP3 2.999542 75 c-Jun RPIB9 -2.183915 
36 CALM2 CSPG 2.96628 76 CASP3 FGF1 2.179099 
37 CALM2 UGDH 2.927373 77 Endothelin1 RPIB9 -2.168576 
38 PRSS23 Endothelin1 2.842801 78 PRSS23 CALM2 -2.163368 
39 PLD RPIB9 -2.768838 79 TGFb-R2 CFH -2.136859 
40 CASP3 SMAD3 -2.728214 80 BTF3 CALM2 -2.130973 
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81 FZD4 FZD4 2.128543 126 ICAM1 ICAM1 1.642936
82 c-Jun c-Jun 2.125499 127 PLD PRSS23 1.642682
83 NOS3 NOS3 2.098091 128 PRG KLF6 -1.637824
84 CYR61 CXCL12 -2.091655 129 TGFb1 TGFb1 1.633198
85 CALM2 c-Jun 2.078061 130 RPIB9 FGF1 1.620557
86 ATP6V0D1 CSPG 2.07361 131 CALM2 FZD4 1.619776
87 CASP3 FZD4 2.062084 132 PLD CFL1 1.604756
88 CFL1 UGDH -2.052853 133 CASP3 GCA 1.576945
89 ATP6V0D1 CFH -2.044165 134 CFL1 KLF6 1.576523
90 TGFb-R2 TGFb-R2 2.036906 135 BTF3 SMAD2 -1.555074
91 Endothelin1 CFL1 2.024652 136 CASP3 BTF3 -1.546986
92 GCA GCA 1.996602 137 c-Jun FGF1 1.54171
93 GNAS2 GAPDH 1.987186 138 ATP6V0D1 PRSS23 1.535841
94 RHOJ GAPDH -1.982485 139 c-Jun CXCL12 1.532972
95 CFL1 CFH 1.979011 140 Endothelin1 PLD -1.523676
96 ATP6V0D1 CALM2 -1.974402 141 CYR61 CALM2 1.517557
97 BTF3 FGF1 -1.968983 142 ATP6V0D1 PLD -1.496417
98 SMAD2 SMAD2 1.966927 143 CDYL12 CXCL12 1.487483
99 FZD4 GAPDH -1.96532 144 CDYL12 GAPDH -1.482582
100 CFL1 NOS3 -1.962628 145 GTPBP4 CFL1 -1.480965
101 CYR61 FGF1 1.954061 146 CASP3 PHGDH -1.457463
102 Endothelin1 PRSS23 1.94045 147 GTPBP4 CXCL12 1.457217
103 CALM2 CFH -1.92955 148 PRG PRG 1.456033
104 CFL1 AQP1 1.92925 149 CASP3 KLF6 1.4507
105 RHOJ CXCL12 1.921979 150 PRG CFH -1.450461
106 TOR3A TOR3A 1.904106 151 CDYL12 CALM2 -1.443827
107 TGFb-R2 RPIB9 1.903911 152 GNAS2 CALM2 1.438364
108 GTPBP4 GTPBP4 1.89768 153 TGFb1 CFL1 -1.433114
109 CDYL12 CDYL12 1.897598 154 PRSS23 CFH -1.425859
110 TOR3A GAPDH -1.895986 155 TGFb-R2 CALM2 -1.424873
111 KLF6 CXCL12 -1.892251 156 Endothelin1 AQP1 -1.423115
112 GDI2 GDI2 1.886837 157 CASP3 TGFb1 1.402141
113 PHGDH PHGDH 1.853456 158 CASP3 GAPDH -1.386159
114 BTF3 CFH -1.81942 159 PLD GAPDH -1.376722
115 PRSS23 CSPG 1.817921 160 PRSS23 KLF6 -1.375956
116 CALM2 PRG -1.799347 161 PRG UGDH 1.348567
117 CALM2 SMAD2 -1.782508 162 ICAM1 CXCL12 1.345553
118 BTF3 PLD -1.748211 163 TGFb-R2 CFL1 -1.336576
119 BTF3 ICAM11 -1.74477 164 ICAM1 FGF1 1.334682
120 CYR61 AQP1 1.733734 165 PRSS23 UGDH 1.333416
121 PRG CSPG 1.721634 166 KLF6 RPIB9 -1.329022
122 CFL1 RPIB9 -1.715203 167 PHGDH FGF1 1.327598
123 KLF6 AQP1 1.664461 168 PRSS23 GAPDH -1.317217
124 PRG CALM2 -1.656693 169 CYR61 ICAM1 1.315667
125 CFL1 FZD4 -1.654806 170 Endothelin1 GAPDH -1.313102
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171 UGDH UGDH 1.310948 216 Endothelin1 HOXA3 -1.073105 
172 KLF6 CALM2 1.30467 217 Endothelin1 NOS3 1.072445 
173 PLD AQP1 -1.304656 218 GTPBP4 PRG 1.068494 
174 CASP3 CYR61 1.290601 219 CXCL12 CXCL12 1.068447 
175 KLF6 CSPG 1.286562 220 KLF6 ICAM1 1.068114 
176 GAPDH AQP1 -1.285852 221 CALM2 KLF6 -1.06752 
177 PRG CYR61 1.282092 222 GTPBP4 FGF1 1.067299 
178 RHOJ AQP1 -1.280362 223 TOR3A CALM2 -1.060599 
179 KLF6 PRSS23 -1.269263 224 PRSS23 CFL1 -1.05331 
180 FZD4 CXCL12 1.262295 225 GNAS2 FGF1 1.052674 
181 GNAS2 CFH 1.257652 226 CALM2 ICAM1 -1.051629 
182 c-Jun CSPG -1.254964 227 TGFb1 CXCL12 1.041784 
183 PRSS23 CYR61 1.253514 228 CYR61 CFL1 1.035112 
184 PLD CALM2 1.249145 229 GNAS2 Endothelin1 -1.031415 
185 ATP6V0D1 SMAD2 -1.246196 230 TOR3A CXCL12 1.026558 
186 Endothelin1 c-Jun 1.243444 231 KLF6 CFH 1.022732 
187 ATP6V0D1 FGF1 -1.242175 232 CFL1 SMAD2 1.019112 
188 SMAD3 CSPG 1.235187 233 CDYL12 AQP1 -1.017664 
189 NOS3 RPIB9 -1.233677 234 TGFb-R2 CSPG 1.016944 
190 Endothelin1 SMAD3 1.230222 235 RPIB9 CFH 1.010395 
191 BTF3 BTF3 1.229077 236 PRSS23 AQP1 1.008426 
192 KLF6 KLF6 1.226434 237 TOR3A CFL1 -1.00681 
193 PLD SMAD3 1.219833 238 ICAM1 PRG 0.999998 
194 KLF6 PLD 1.211519 239 CALM2 GCA 0.996761 
195 c-Jun GAPDH -1.179839 240 FZD4 CALM2 -0.994436 
196 CYR61 Endothelin1 -1.162037 241 PHGDH PLD 0.992965 
197 RHOJ CFH -1.151993 242 ATP6V0D1 c-Jun 0.988746 
198 CYR61 PRSS23 -1.150767 243 ICAM1 PLD 0.987355 
199 c-Jun Endothelin1 -1.147760 244 SMAD2 CXCL12 0.985341 
200 CFL1 GDI2 1.145122 245 PRG PLD -0.980209 
201 AQP1 CSPG 1.141788 246 CXCL12 AQP1 0.979658 
202 CASP3 ATP6V0D1 1.140607 247 TGFb-R2 TGFb1 -0.978712 
203 c-Jun PRG 1.136098 248 CALM2 HOXA3 -0.977092 
204 RPIB9 Endothelin1 -1.131415 249 RPIB9 KLF6 0.974219 
205 CYR61 SMAD2 1.122306 250 CALM2 SMAD3 0.970076 
206 TGFb1 CSPG 1.12179 251 CASP3 UGDH 0.97002 
207 Endothelin1 CYR61 1.118653 252 PLD HOXA3 -0.969137 
208 CALM2 PHGDH -1.105632 253 CFL1 TGFb1 -0.968707 
209 FZD4 CFL1 -1.100342 254 GAPDH PRSS23 0.968161 
210 BTF3 PRSS23 1.095389 255 PLD c-Jun 0.965911 
211 KLF6 SMAD2 1.0852 256 RHOJ CFL1 -0.96468 
212 CALM2 RHOJ 1.081526 257 GTPBP4 PLD 0.964364 
213 CALM2 BTF3 -1.077063 258 NOS3 CXCL12 0.962163 
214 CALM2 TGFb1 1.074866 259 CFH CALM2 -0.960891 
215 BTF3 CYR61 1.073831 260 TGFb-R2 CXCL12 0.954057 
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261 CASP3 CSPG 0.953982 306 TGFb-R2 GAPDH -0.819272
262 RPIB9 RPIB9 -0.947515 307 KLF6 BTF3 0.813969
263 PHGDH CFL1 -0.946539 308 BTF3 Endothelin1 0.813671
264 CYR61 UGDH -0.938486 309 TOR3A CFH -0.813397
265 FZD4 GCA -0.936292 310 ATP6V0D1 CYR61 0.81192
266 PRSS23 SMAD3 -0.935454 311 ATP6V0D1 PHGDH -0.808789
267 c-Jun KLF6 0.933512 312 CALM2 CXCL12 0.807208
268 BTF3 CFL1 -0.933266 313 ATP6V0D1 RHOJ 0.806569
269 RPIB9 AQP1 -0.930272 314 Endothelin1 PRG -0.803353
270 CFH AQP1 -0.929077 315 CYR61 PLD 0.799185
271 KLF6 PRG 0.926734 316 CASP3 CFL1 0.798349
272 ATP6V0D1 CFL1 -0.920006 317 GAPDH c-Jun 0.79265
273 CYR61 BTF3 0.91894 318 NOS3 FGF1 0.792039
274 ATP6V0D1 UGDH 0.917983 319 ATP6V0D1 Endothelin1 0.790161
275 RPIB9 CSPG -0.916101 320 CALM2 GNAS2 -0.789899
276 KLF6 Endothelin1 -0.913173 321 PLD CYR61 0.784333
277 BTF3 NOS3 0.909243 322 GDI2 NOS3 0.782998
278 BTF3 UGDH 0.904876 323 UGDH FGF1 0.781267
279 ATP6V0D1 ICAM1 0.89925 324 GTPBP4 CALM2 -0.780322
280 ICAM1 CFL1 -0.898077 325 CFH PRSS23 0.780167
281 CFL1 SMAD3 -0.894491 326 RPIB9 GAPDH -0.777969
282 ATP6V0D1 NOS3 0.893727 327 GAPDH SMAD3 0.777137
283 GCA CFL1 -0.892572 328 CASP3 RAMP3 -0.776737
284 CASP3 CALM2 0.888856 329 RHOJ CSPG 0.776246
285 RHOJ CALM2 -0.887787 330 RPIB9 SMAD3 0.769392
286 PLD NOS3 0.887649 331 KLF6 CYR61 -0.761481
287 Endothelin1 RAMP3 -0.880815 332 CDYL12 CFL1 -0.757179
288 PRSS23 RAMP3 -0.880577 333 UGDH RPIB9 -0.756906
289 PRG GCA 0.880418 334 CYR61 PHGDH 0.753908
290 PRG AQP1 0.879461 335 UGDH CSPG -0.752372
291 TOR3A RPIB9 0.872244 336 CASP3 RPIB9 0.744745
292 SMAD3 CXCL12 0.865239 337 RPIB9 PHGDH -0.74399
293 PLD FGF1 0.863824 338 GDI2 PRSS23 0.7428
294 BTF3 PRG -0.863597 339 TGFb-R2 HOXA3 0.742079
295 RPIB9 PRG 0.863141 340 GNAS2 CYR61 -0.74119
296 Endothelin1 FZD4 0.861509 341 PRSS23 HOXA3 0.740413
297 SMAD2 FGF1 0.856169 342 PHGDH PRG 0.739949
298 FZD4 AQP1 -0.853477 343 Endothelin1 CALM2 0.738925
299 TOR3A AQP1 -0.847746 344 TOR3A GCA -0.736713
300 PRSS23 PRSS23 0.847285 345 ICAM1 RPIB9 -0.735808
301 GDI2 RPIB9 -0.841091 346 TGFb1 HOXA3 0.735693
302 GNAS2 CFL1 0.836314 347 KLF6 UGDH -0.72825
303 GCA CXCL12 0.836269 348 GAPDH CALM2 -0.721993
304 PRG RAMP3 -0.82963 349 HOXA3 GAPDH -0.721046
305 FZD4 CFH -0.826351 350 CFL1 TOR3A 0.720497
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351 PLD CSPG -0.720347 396 GAPDH CXCL12 0.62672 
352 CFH CFL1 -0.718437 397 CDYL12 PRSS23 0.626512 
353 TGFb-R2 Endothelin1 0.715016 398 CYR61 PRG 0.620565 
354 SMAD2 PRG 0.712885 399 ICAM1 CFH 0.620361 
355 PLD PLD -0.709276 400 BTF3 GAPDH -0.619802 
356 BTF3 TGFb-R2 -0.707906 401 ATP6V0D1 GCA -0.619129 
357 BTF3 c-Jun 0.704005 402 GDI2 PLD -0.619083 
358 GTPBP4 GCA -0.702158 403 CALM2 CFL1 0.616158 
359 TGFb1 RPIB9 0.701872 404 PRSS23 BTF3 0.613626 
360 CYR61 c-Jun -0.699378 405 TOR3A HOXA3 0.612508 
361 RAMP3 GAPDH -0.697487 406 PHGDH KLF6 0.611256 
362 PHGDH CXCL12 0.691945 407 CDYL12 BTF3 -0.610371 
363 NOS3 CSPG -0.688913 408 TOR3A CSPG 0.609698 
364 PLD RAMP3 -0.686776 409 c-Jun CALM2 0.607867 
365 GDI2 CFL1 0.684758 410 CASP3 CDYL12 -0.604778 
366 RHOJ PRSS23 0.683442 411 GAPDH PLD -0.604335 
367 RHOJ GCA -0.682826 412 BTF3 RAMP3 -0.603226 
368 RPIB9 BTF3 -0.682635 413 CFH CSPG 0.601111 
369 PRSS23 PLD -0.680746 414 CDYL12 PLD -0.599745 
370 ICAM1 CSPG -0.677438 415 PLD CXCL12 0.594866 
371 ATP6V0D1 CDYL12 -0.676129 416 TGFb-R2 GCA -0.593891 
372 PRG PHGDH 0.672652 417 GNAS2 UGDH -0.593696 
373 PRSS23 CDYL12 0.672295 418 GAPDH CASP3 0.592818 
374 TGFb1 KLF6 0.67219 419 ICAM1 GCA -0.59269 
375 PLD FZD4 0.67139 420 GNAS2 KLF6 0.592359 
376 BTF3 RHOJ 0.665645 421 BTF3 PHGDH -0.591673 
377 RHOJ BTF3 -0.663887 422 ATP6V0D1 PRG -0.589468 
378 CYR61 FZD4 -0.658798 423 TGFb1 PRG 0.588396 
379 BTF3 FZD4 0.657172 424 Endothelin1 RHOJ 0.586128 
380 RPIB9 GCA -0.654921 425 PRG CDYL12 0.581995 
381 ICAM1 KLF6 0.653758 426 c-Jun GCA -0.581458 
382 CFH GCA -0.652579 427 FZD4 PRG 0.579215 
383 TGFb1 PLD 0.651457 428 CFH CXCL12 0.578945 
384 TGFb-R2 AQP1 -0.650353 429 CALM2 TOR3A -0.578279 
385 PLD KLF6 0.646984 430 CFH HOXA3 0.571996 
386 PLD RHOJ 0.644232 431 CFL1 ICAM1 0.571748 
387 GTPBP4 HOXA3 0.644008 432 c-Jun CFH 0.566377 
388 PHGDH CSPG -0.641865 433 CALM2 GDI2 -0.565448 
389 CDYL12 PHGDH -0.64088 434 GTPBP4 KLF6 0.565255 
390 Endothelin1 GCA 0.636822 435 NOS3 GAPDH -0.562523 
391 ICAM1 Endothelin1 -0.63608 436 PRG SMAD3 -0.562137 
392 CFL1 TGFb-R2 -0.633826 437 PLD CFH 0.559681 
393 TGFb1 CALM2 -0.633426 438 RPIB9 RHOJ 0.554255 
394 GNAS2 AQP1 0.631276 439 CFH Endothelin1 0.552145 
395 ATP6V0D1 FZD4 0.629283 440 c-Jun UGDH -0.55193 
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441 TGFb1 GCA -0.54898 486 CYR61 TGFb-R2 0.488599
442 AQP1 CXCL12 -0.548603 487 CFH PHGDH -0.488553
443 TGFb-R2 RHOJ 0.547531 488 KLF6 RAMP3 0.488305
444 FZD4 CSPG 0.546913 489 RHOJ HOXA3 0.486262
445 FZD4 HOXA3 0.545993 490 c-Jun SMAD3 0.485082
446 BTF3 CASP3 -0.545044 491 GDI2 GAPDH -0.484308
447 CASP3 GTPBP4 0.542718 492 TOR3A PHGDH -0.483153
448 ICAM1 PHGDH -0.537722 493 CYR61 GNAS2 0.48172
449 FZD4 RPIB9 0.537328 494 CDYL12 SMAD2 -0.480506
450 CDYL12 NOS3 0.53664 495 NOS3 PRSS23 0.48024
451 GCA GAPDH -0.534175 496 KLF6 c-Jun -0.479879
452 KLF6 NOS3 -0.532306 497 BTF3 GCA -0.479607
453 CXCL12 RPIB9 0.532244 498 CASP3 GDI2 0.478653
454 PHGDH CFH 0.530371 499 BTF3 TGFb1 -0.478121
455 PLD PHGDH -0.530245 500 TGFb-R2 FGF1 -0.477687
456 HOXA3 PRSS23 0.526719 501 SMAD2 CSPG -0.477231
457 CYR61 NOS3 -0.525726 502 RPIB9 UGDH -0.476633
458 PLD Endothelin1 -0.523273 503 SMAD2 Endothelin1 -0.476078
459 GDI2 AQP1 -0.522203 504 GCA FGF1 0.475266
460 SMAD3 CALM2 -0.51931 505 CXCL12 ICAM1 0.473598
461 CSPG GAPDH -0.514425 506 CXCL12 CFL1 0.470731
462 GCA CALM2 -0.514125 507 SMAD3 AQP1 -0.470039
463 GTPBP4 BTF3 -0.511736 508 KLF6 HOXA3 0.469992
464 RHOJ PHGDH -0.509805 509 SMAD3 PRG 0.46935
465 RPIB9 CYR61 -0.509635 510 RPIB9 CDYL12 -0.466737
466 GDI2 SMAD3 0.509539 511 FZD4 PRSS23 0.465435
467 GAPDH Endothelin1 0.506889 512 TGFb-R2 ICAM1 -0.463773
468 CFL1 CASP3 0.506538 513 TOR3A Endothelin1 0.463403
469 AQP1 FGF1 -0.505472 514 GTPBP4 CYR61 -0.46138
470 PLD GCA 0.504969 515 KLF6 CASP3 0.459868
471 c-Jun PLD 0.504646 516 HOXA3 RPIB9 -0.458962
472 TGFb-R2 BTF3 -0.504576 517 SMAD2 RPIB9 -0.457652
473 FZD4 PHGDH -0.503613 518 CFL1 GNAS2 0.45734
474 RPIB9 PLD 0.50319 519 GCA HOXA3 0.457223
475 GNAS2 PLD 0.501432 520 FZD4 BTF3 -0.456124
476 ICAM1 c-Jun -0.499641 521 PHGDH GCA -0.455638
477 GTPBP4 PHGDH -0.499135 522 CFL1 CALM2 0.452025
478 PHGDH CYR61 -0.497396 523 BTF3 GNAS2 -0.450612
479 TGFb-R2 UGDH 0.496391 524 Endothelin1 TGFb1 0.450065
480 TOR3A RHOJ 0.496005 525 CDYL12 RHOJ 0.449222
481 SMAD2 CFL1 -0.494962 526 CDYL12 UGDH 0.448834
482 GAPDH CYR61 0.494133 527 CFH FGF1 -0.447435
483 HOXA3 AQP1 -0.4941 528 Endothelin1 Endothelin1 0.44604
484 ICAM1 CYR61 -0.493526 529 GDI2 c-Jun 0.446012
485 KLF6 CFL1 0.492448 530 c-Jun CYR61 -0.444088
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531 SMAD2 KLF6 0.44373 576 CDYL12 RPIB9 0.397418 
532 SMAD2 CFH 0.44157 577 CYR61 TGFb1 0.39706 
533 ATP6V0D1 SMAD3 0.441503 578 GNAS2 ICAM1 0.39632 
534 SMAD2 PLD 0.437831 579 SMAD2 GCA -0.393349 
535 ATP6V0D1 TOR3A -0.43736 580 TGFb-R2 GDI2 0.392268 
536 SMAD3 CFL1 -0.436647 581 GTPBP4 TGFb1 -0.392196 
537 GNAS2 PRSS23 -0.436322 582 Endothelin1 CXCL12 0.391085 
538 CXCL12 CSPG -0.433789 583 GTPBP4 GDI2 0.389734 
539 GTPBP4 c-Jun -0.433004 584 TGFb1 GDI2 0.388874 
540 NOS3 SMAD3 0.431952 585 UGDH CFH 0.388493 
541 CDYL12 GCA -0.429901 586 RHOJ NOS3 0.386474 
542 ATP6V0D1 RAMP3 -0.429829 587 CYR61 RHOJ -0.386008 
543 CFH UGDH 0.429609 588 GAPDH HOXA3 0.385663 
544 GAPDH UGDH 0.428592 589 CFH c-Jun 0.384285 
545 ICAM1 BTF3 -0.42817 590 PHGDH RAMP3 0.383569 
546 KLF6 TGFb-R2 0.427413 591 PHGDH RPIB9 -0.383497 
547 PLD TGFb1 0.427115 592 c-Jun BTF3 -0.381775 
548 PHGDH Endothelin1 -0.426788 593 ICAM1 RAMP3 0.381481 
549 HOXA3 SMAD3 0.426192 594 RHOJ RPIB9 0.380013 
550 CFH RHOJ 0.426008 595 TOR3A PRG 0.37954 
551 CFH RPIB9 0.424983 596 SMAD2 CYR61 -0.378648 
552 PRSS23 TOR3A 0.423672 597 ATP6V0D1 BTF3 -0.376401 
553 FZD4 CASP3 0.423494 598 CSPG FGF1 0.37619 
554 PRG BTF3 0.422625 599 RAMP3 CXCL12 0.373445 
555 PHGDH c-Jun -0.421911 600 GCA PRG 0.373063 
556 GNAS2 NOS3 -0.421791 601 ICAM1 GDI2 0.372268 
557 GAPDH ICAM1 0.419292 602 TGFb1 BTF3 -0.371438 
558 SMAD3 CASP3 0.417966 603 AQP1 CASP3 0.369031 
559 SMAD2 HOXA3 0.417238 604 CFL1 BTF3 -0.368529 
560 SMAD3 KLF6 0.417051 605 Endothelin1 KLF6 0.367888 
561 CXCL12 SMAD2 0.416041 606 PHGDH HOXA3 0.36762 
562 BTF3 ATP6V0D1 0.414528 607 KLF6 FZD4 -0.367284 
563 ATP6V0D1 GNAS2 -0.414404 608 UGDH CALM2 0.367226 
564 PRSS23 TGFb1 -0.414377 609 GCA PHGDH -0.367007 
565 TOR3A BTF3 -0.413956 610 PRSS23 PHGDH 0.365794 
566 RPIB9 CFL1 -0.412118 611 CALM2 TGFb-R2 0.365716 
567 HOXA3 PLD -0.411843 612 RPIB9 RAMP3 0.362849 
568 GTPBP4 RAMP3 0.41166 613 TGFb1 c-Jun -0.361341 
569 TOR3A PRSS23 0.410234 614 UGDH PRG 0.359132 
570 GDI2 CYR61 0.409766 615 GTPBP4 CFH 0.357408 
571 TGFb1 PHGDH -0.407542 616 NOS3 Endothelin1 -0.357291 
572 TGFb-R2 NOS3 0.402942 617 TGFb-R2 PRSS23 0.355099 
573 CDYL12 SMAD3 0.401069 618 RAMP3 CALM2 -0.354093 
574 GAPDH CSPG 0.400566 619 CXCL12 CALM2 0.352665 
575 PLD PRG -0.397471 620 TGFb-R2 SMAD2 -0.349989 
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621 NOS3 CFH 0.34896 666 PHGDH GDI2 0.317786
622 HOXA3 c-Jun 0.347007 667 GAPDH RAMP3 -0.317611
623 CFH CFH 0.345406 668 HOXA3 NOS3 0.3172
624 Endothelin1 GDI2 -0.345289 669 RHOJ UGDH 0.316683
625 TOR3A UGDH 0.344782 670 TGFb1 RHOJ 0.316043
626 UGDH SMAD3 0.344669 671 FZD4 GDI2 0.315538
627 RHOJ PRG 0.342943 672 RHOJ SMAD3 0.313565
628 CFH CASP3 0.341853 673 UGDH PLD 0.312842
629 CYR61 KLF6 0.34182 674 PRSS23 PRG -0.311732
630 GNAS2 c-Jun -0.341702 675 ICAM1 RHOJ 0.311002
631 ICAM1 UGDH -0.339851 676 CFH BTF3 -0.309593
632 PLD CDYL12 -0.338918 677 GAPDH FZD4 0.308799
633 GCA PLD 0.337256 678 UGDH CDYL12 0.307307
634 ICAM1 HOXA3 0.337033 679 PLD GDI2 -0.307012
635 GDI2 RAMP3 -0.336962 680 PLD TOR3A -0.303559
636 GAPDH CFH -0.336479 681 Endothelin1 TOR3A -0.303502
637 GNAS2 GCA -0.335394 682 CDYL12 c-Jun 0.303417
638 GNAS2 PRG 0.335174 683 AQP1 CFH -0.30251
639 GNAS2 SMAD2 0.334785 684 SMAD3 RPIB9 -0.302382
640 RHOJ SMAD2 -0.33421 685 AQP1 ICAM1 0.301902
641 PRG FZD4 0.333999 686 BTF3 CDYL12 -0.301147
642 TGFb-R2 FZD4 0.332204 687 CDYL12 Endothelin1 0.300286
643 CFL1 RHOJ -0.332018 688 HOXA3 CXCL12 0.299946
644 GCA KLF6 0.331737 689 PRG CFL1 -0.298701
645 KLF6 RHOJ -0.331237 690 Endothelin1 UGDH 0.298661
646 GAPDH FGF1 -0.330092 691 TGFb1 PRSS23 -0.298462
647 GNAS2 HOXA3 -0.329482 692 UGDH SMAD2 0.298387
648 UGDH NOS3 -0.32921 693 GDI2 FZD4 0.298291
649 CFL1 CDYL12 -0.328737 694 PRG TOR3A 0.298233
650 GAPDH NOS3 0.326284 695 RHOJ c-Jun 0.295836
651 SMAD3 HOXA3 0.324979 696 FZD4 Endothelin1 0.295482
652 PRG GNAS2 -0.324713 697 GDI2 HOXA3 -0.293912
653 FGF1 CSPG -0.324237 698 NOS3 KLF6 0.293661
654 FZD4 RHOJ 0.322986 699 FGF1 PLD 0.293499
655 GAPDH CFL1 -0.322811 700 AQP1 c-Jun 0.293258
656 CDYL12 PRG 0.322572 701 RPIB9 CASP3 0.292656
657 CXCL12 TGFb-R2 0.322165 702 RHOJ FGF1 -0.292086
658 TGFb1 ICAM1 -0.32212 703 PRSS23 GNAS2 -0.291544
659 TGFb1 FGF1 0.321726 704 SMAD3 BTF3 -0.290751
660 GAPDH PHGDH -0.321702 705 GAPDH BTF3 -0.290265
661 c-Jun PHGDH -0.321302 706 RAMP3 CFH -0.289608
662 UGDH ICAM1 0.320821 707 TOR3A CASP3 0.289129
663 Endothelin1 PHGDH -0.320208 708 PRG NOS3 0.288936
664 SMAD2 PHGDH -0.320187 709 CXCL12 Endothelin1 0.28751
665 CDYL12 KLF6 0.319906 710 GCA RPIB9 0.286851
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711 HOXA3 RHOJ 0.284675 756 SMAD2 RAMP3 0.255614 
712 UGDH AQP1 0.284509 757 FGF1 PRG 0.255403 
713 GCA BTF3 -0.284124 758 HOXA3 PHGDH -0.255345 
714 AQP1 CFL1 0.283436 759 CXCL12 CDYL12 0.254639 
715 CFH SMAD3 0.28332 760 AQP1 SMAD3 0.253928 
716 FZD4 SMAD3 0.283262 761 PLD BTF3 -0.252284 
717 PHGDH PRSS23 -0.283235 762 Endothelin1 SMAD2 -0.251569 
718 BTF3 GDI2 0.280371 763 CDYL12 CSPG 0.250842 
719 RHOJ GDI2 0.277609 764 PHGDH TGFb-R2 -0.25053 
720 PLD SMAD2 -0.277574 765 TGFb-R2 KLF6 0.250044 
721 FZD4 PLD 0.277162 766 GTPBP4 CSPG -0.249621 
722 HOXA3 CYR61 0.277071 767 RHOJ ICAM1 -0.249554 
723 CYR61 ATP6V0D1 -0.276139 768 RPIB9 NOS3 0.249131 
724 TOR3A GDI2 0.275635 769 GAPDH RHOJ 0.248126 
725 PHGDH ICAM1 -0.27431 770 SMAD3 c-Jun 0.248093 
726 ATP6V0D1 TGFb-R2 -0.273231 771 RPIB9 TGFb1 0.247692 
727 RAMP3 CFL1 -0.273036 772 SMAD2 UGDH -0.247075 
728 TGFb1 CYR61 -0.272378 773 CDYL12 TGFb1 0.246506 
729 CFH PRG 0.272365 774 PHGDH TOR3A 0.245874 
730 TGFb-R2 PHGDH -0.271544 775 c-Jun CDYL12 -0.245587 
731 GTPBP4 NOS3 -0.270796 776 UGDH CASP3 0.245382 
732 AQP1 CYR61 0.270721 777 CFH GNAS2 -0.244501 
733 PRG PRSS23 -0.270675 778 GTPBP4 RHOJ 0.242985 
734 RHOJ CASP3 0.268817 779 CFH NOS3 0.242949 
735 CDYL12 HOXA3 0.268072 780 PHGDH UGDH -0.242587 
736 CASP3 PLD -0.267839 781 GCA GDI2 0.242542 
737 GTPBP4 RPIB9 0.267293 782 PRG HOXA3 0.242248 
738 RHOJ FZD4 0.26688 783 FGF1 CFL1 -0.241329 
739 TGFb1 RAMP3 0.265818 784 ICAM1 CDYL12 -0.241314 
740 SMAD2 BTF3 -0.265004 785 HOXA3 FZD4 0.239946 
741 GTPBP4 FZD4 -0.262349 786 FGF1 HOXA3 0.239667 
742 CDYL12 FZD4 0.261701 787 UGDH Endothelin1 -0.239631 
743 SMAD3 PHGDH -0.261475 788 CXCL12 KLF6 -0.239119 
744 NOS3 PHGDH -0.261336 789 CALM2 ATP6V0D1 0.239007 
745 RAMP3 AQP1 -0.260592 790 CFH FZD4 0.238589 
746 PHGDH TGFb1 -0.260175 791 SMAD3 PRSS23 0.238448 
747 KLF6 CDYL12 0.259899 792 FGF1 KLF6 0.23843 
748 GCA RHOJ 0.259841 793 HOXA3 CFL1 0.238254 
749 SMAD3 GCA -0.259429 794 NOS3 BTF3 -0.237475 
750 PRSS23 RHOJ -0.258409 795 PRSS23 GDI2 0.236799 
751 SMAD2 RHOJ 0.258073 796 FZD4 UGDH 0.236679 
752 KLF6 GNAS2 0.258047 797 CSPG CXCL12 0.234863 
753 PHGDH RHOJ 0.257652 798 GTPBP4 PRSS23 -0.234567 
754 GTPBP4 CDYL12 -0.257282 799 GDI2 CALM2 0.234539 
755 c-Jun GNAS2 0.255923 800 Endothelin1 BTF3 -0.234424 
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801 RPIB9 TOR3A -0.234201 846 PHGDH NOS3 -0.205624
802 PHGDH BTF3 -0.234119 847 CYR61 GCA -0.204767
803 CDYL12 ICAM1 -0.232719 848 NOS3 PRG 0.204702
804 PRSS23 GCA 0.232562 849 HOXA3 FGF1 0.203323
805 HOXA3 KLF6 0.232501 850 GTPBP4 Endothelin1 -0.202608
806 FZD4 TGFb-R2 -0.231483 851 GAPDH KLF6 0.202552
807 GNAS2 TGFb1 0.231002 852 c-Jun CASP3 0.202097
808 TGFb-R2 CYR61 0.230689 853 RAMP3 CSPG 0.201877
809 RHOJ TGFb-R2 -0.229026 854 AQP1 RAMP3 -0.201398
810 CXCL12 GCA 0.2288 855 CFH TGFb1 0.201212
811 PRG RHOJ -0.228541 856 FZD4 GNAS2 -0.199054
812 RHOJ KLF6 0.227239 857 GCA AQP1 -0.198923
813 BTF3 HOXA3 -0.226815 858 AQP1 UGDH 0.19852
814 BTF3 SMAD3 -0.225375 859 ICAM1 TOR3A 0.198179
815 GAPDH PRG 0.224281 860 RHOJ Endothelin1 0.197263
816 TGFb-R2 GNAS2 -0.223673 861 FGF1 CDYL12 0.196979
817 TOR3A FGF1 -0.223439 862 CYR61 CASP3 0.196327
818 TOR3A GNAS2 -0.222805 863 TOR3A c-Jun 0.194724
819 GDI2 RHOJ 0.221758 864 GDI2 CASP3 0.19451
820 GAPDH TOR3A -0.220995 865 NOS3 AQP1 0.194468
821 SMAD2 SMAD3 0.220741 866 CXCL12 GAPDH -0.193411
822 PRG c-Jun -0.220247 867 PHGDH AQP1 0.192622
823 RHOJ GNAS2 -0.21972 868 ICAM1 TGFb-R2 -0.192266
824 RPIB9 HOXA3 0.219708 869 GTPBP4 TOR3A 0.191929
825 AQP1 SMAD2 0.219555 870 CSPG CALM2 -0.191271
826 UGDH KLF6 0.21904 871 TOR3A SMAD2 -0.190656
827 SMAD3 ICAM1 0.218015 872 AQP1 PLD -0.189371
828 CYR61 GDI2 -0.216719 873 TGFb1 Endothelin1 -0.18914
829 GNAS2 TOR3A -0.214781 874 CXCL12 PHGDH 0.189017
830 GTPBP4 CASP3 0.214397 875 GNAS2 BTF3 0.186395
831 c-Jun RAMP3 0.214328 876 GTPBP4 TGFb-R2 -0.185649
832 NOS3 GCA -0.213649 877 CASP3 c-Jun 0.185592
833 TOR3A SMAD3 0.213453 878 CDYL12 GNAS2 -0.184377
834 NOS3 RHOJ 0.212726 879 SMAD2 CALM2 -0.183287
835 GDI2 CXCL12 0.211289 880 RAMP3 HOXA3 0.183082
836 GDI2 GCA 0.210284 881 TOR3A NOS3 0.18301
837 NOS3 UGDH -0.210265 882 RHOJ CDYL12 -0.182935
838 Endothelin1 CSPG -0.210143 883 PHGDH CDYL12 -0.18084
839 PRG SMAD2 0.209534 884 GDI2 TGFb1 0.180345
840 NOS3 CDYL12 -0.208658 885 RPIB9 PRSS23 0.180337
841 UGDH GAPDH 0.207119 886 Endothelin1 CASP3 0.180086
842 HOXA3 RAMP3 -0.206556 887 RAMP3 PHGDH -0.180068
843 CFH GDI2 0.205872 888 RPIB9 GDI2 0.178603
844 TGFb1 SMAD2 -0.205828 889 FZD4 TGFb1 -0.178481
845 SMAD3 PLD -0.205723 890 NOS3 CALM2 0.178299
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891 GTPBP4 ATP6V0D1 0.177547 936 GCA CSPG -0.153859 
892 PHGDH FZD4 -0.17661 937 PRG TGFb1 -0.153684 
893 CDYL12 CYR61 0.175548 938 CALM2 CASP3 -0.153562 
894 FZD4 KLF6 0.175129 939 TGFb1 GAPDH 0.153084 
895 SMAD2 CASP3 0.174729 940 GNAS2 CDYL12 -0.153049 
896 SMAD2 GDI2 0.174495 941 ICAM1 FZD4 -0.15303 
897 c-Jun GDI2 0.172997 942 NOS3 c-Jun 0.152776 
898 KLF6 TOR3A 0.172837 943 PRG GAPDH 0.152326 
899 SMAD2 AQP1 -0.171812 944 RAMP3 PRG 0.151859 
900 CDYL12 CASP3 0.170126 945 TGFb-R2 ATP6V0D1 0.151817 
901 CXCL12 CASP3 0.169904 946 CXCL12 TGFb1 0.151731 
902 NOS3 FZD4 0.169745 947 FZD4 RAMP3 0.150172 
903 c-Jun RHOJ 0.169692 948 RAMP3 BTF3 -0.150158 
904 PHGDH CALM2 0.168511 949 CFH TGFb-R2 0.150135 
905 PRG ICAM1 -0.167208 950 UGDH CYR61 -0.148293 
906 KLF6 PHGDH 0.166961 951 NOS3 CYR61 -0.14822 
907 GDI2 KLF6 0.166866 952 UGDH CFL1 0.148204 
908 HOXA3 UGDH 0.166775 953 AQP1 PRSS23 0.147562 
909 AQP1 Endothelin1 0.16569 954 HOXA3 BTF3 -0.14705 
910 TOR3A TGFb-R2 -0.165327 955 BTF3 TOR3A -0.146376 
911 KLF6 ATP6V0D1 -0.164714 956 UGDH TGFb1 0.144615 
912 ATP6V0D1 TGFb1 0.164494 957 BTF3 GTPBP4 -0.144592 
913 CFH CYR61 0.164056 958 CSPG CFL1 -0.144475 
914 PLD TGFb-R2 0.163462 959 BTF3 KLF6 0.144336 
915 RPIB9 CALM2 0.162924 960 PRG GTPBP4 0.143221 
916 GTPBP4 GAPDH -0.162759 961 FGF1 SMAD3 0.143185 
917 PRSS23 SMAD2 0.161709 962 SMAD3 RHOJ 0.143075 
918 CALM2 GTPBP4 -0.161493 963 TOR3A FZD4 0.142345 
919 TOR3A ICAM1 -0.16147 964 SMAD2 CDYL12 -0.140778 
920 RAMP3 RPIB9 0.160901 965 c-Jun PRSS23 0.140679 
921 ICAM1 ATP6V0D1 0.160282 966 FZD4 SMAD2 -0.139913 
922 PHGDH ATP6V0D1 0.160081 967 PRSS23 NOS3 -0.139539 
923 FZD4 c-Jun 0.159408 968 GDI2 PRG -0.139531 
924 AQP1 RPIB9 0.159107 969 PRG ATP6V0D1 0.139465 
925 FGF1 CASP3 0.159011 970 CSPG GCA -0.138902 
926 GTPBP4 ICAM1 -0.158091 971 TGFb1 CFH 0.137997 
927 CDYL12 FGF1 0.157463 972 TOR3A TGFb1 -0.136906 
928 TOR3A KLF6 0.157412 973 c-Jun ICAM1 0.136716 
929 KLF6 GCA 0.156962 974 GAPDH GNAS2 -0.136431 
930 CYR61 SMAD3 -0.156653 975 ICAM1 SMAD3 0.135896 
931 PLD UGDH 0.156602 976 NOS3 CASP3 0.134759 
932 ICAM1 CASP3 0.155861 977 PLD CASP3 0.134269 
933 TGFb1 TGFb-R2 -0.154977 978 AQP1 KLF6 0.134175 
934 Endothelin1 CDYL12 -0.154949 979 AQP1 BTF3 0.134059 
935 SMAD3 RAMP3 0.154578 980 RPIB9 SMAD2 -0.133732 
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981 CXCL12 FGF1 -0.132652 1026 UGDH GNAS2 0.117645
982 RHOJ CYR61 0.131644 1027 GCA SMAD3 0.117338
983 CFL1 ATP6V0D1 0.131621 1028 Endothelin1 TGFb-R2 0.117336
984 SMAD3 CFH -0.13046 1029 ATP6V0D1 KLF6 0.117326
985 ICAM1 PRSS23 -0.12977 1030 CDYL12 ATP6V0D1 0.117312
986 HOXA3 CASP3 0.129217 1031 HOXA3 SMAD2 -0.116524
987 GCA ICAM1 -0.128633 1032 HOXA3 TGFb1 0.116499
988 c-Jun FZD4 -0.128566 1033 CSPG PRSS23 0.116173
989 GAPDH GCA 0.12856 1034 PLD ICAM1 -0.115976
990 TOR3A PLD 0.12787 1035 CASP3 GNAS2 -0.11571
991 GNAS2 PHGDH 0.127728 1036 SMAD3 FZD4 0.115177
992 c-Jun TOR3A -0.127674 1037 RAMP3 SMAD3 0.115017
993 CSPG AQP1 -0.127365 1038 GDI2 PHGDH -0.114569
994 GNAS2 GDI2 -0.127158 1039 CASP3 Endothelin1 -0.113279
995 AQP1 PRG 0.12705 1040 GDI2 UGDH 0.112341
996 FGF1 GDI2 0.126447 1041 RAMP3 RHOJ 0.11189
997 KLF6 FGF1 0.126154 1042 PLD GTPBP4 -0.111398
998 GCA PRSS23 0.125945 1043 c-Jun TGFb1 0.11057
999 CDYL12 TOR3A -0.125409 1044 RPIB9 ATP6V0D1 0.110544
1000 CDYL12 GTPBP4 -0.125345 1045 UGDH RHOJ 0.110438
1001 CASP3 TGFb-R2 0.125311 1046 NOS3 RAMP3 0.110214
1002 SMAD3 FGF1 -0.125278 1047 c-Jun HOXA3 0.109867
1003 RAMP3 CASP3 0.125197 1048 HOXA3 CDYL12 -0.109686
1004 TGFb-R2 PRG 0.124962 1049 TGFb1 ATP6V0D1 0.109299
1005 CXCL12 CYR61 0.123507 1050 CXCL12 RAMP3 -0.107473
1006 GNAS2 SMAD3 0.122901 1051 PLD GNAS2 0.107368
1007 ATP6V0D1 HOXA3 0.122829 1052 FGF1 SMAD2 0.107148
1008 HOXA3 TOR3A -0.122777 1053 SMAD2 c-Jun -0.106852
1009 RHOJ PLD -0.122358 1054 CXCL12 GDI2 -0.106753
1010 SMAD3 CYR61 -0.122251 1055 UGDH HOXA3 0.106492
1011 SMAD3 NOS3 0.121789 1056 FZD4 FGF1 -0.106148
1012 RPIB9 ICAM1 -0.121627 1057 GDI2 CFH -0.105751
1013 RAMP3 PRSS23 0.121545 1058 FGF1 GCA -0.105136
1014 TGFb-R2 PLD 0.121529 1059 GCA CDYL12 -0.105097
1015 SMAD3 GAPDH 0.120993 1060 FZD4 CDYL12 -0.104829
1016 c-Jun CFL1 -0.120851 1061 GCA CASP3 0.10447
1017 HOXA3 CSPG -0.120706 1062 GNAS2 FZD4 -0.104385
1018 KLF6 GDI2 -0.120326 1063 SMAD3 TGFb-R2 -0.104073
1019 UGDH CXCL12 -0.119975 1064 PRG TGFb-R2 0.103448
1020 ATP6V0D1 RPIB9 -0.119441 1065 CXCL12 ATP6V0D1 -0.102499
1021 FGF1 PRSS23 -0.119329 1066 AQP1 TGFb-R2 0.102489
1022 NOS3 TGFb1 0.11867 1067 GDI2 TOR3A -0.102458
1023 GCA SMAD2 -0.118574 1068 CXCL12 RHOJ -0.101821
1024 GDI2 CSPG -0.118149 1069 TGFb1 TOR3A 0.101178
1025 GAPDH TGFb1 0.117956 1070 TGFb-R2 c-Jun 0.101163
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1071 FZD4 ICAM1 -0.10025 1116 SMAD2 FZD4 -0.080911 
1072 AQP1 GAPDH 0.100185 1117 UGDH GDI2 0.080081 
1073 ATP6V0D1 GTPBP4 -0.100111 1118 TGFb-R2 CASP3 0.078106 
1074 TOR3A CDYL12 -0.099789 1119 RAMP3 UGDH 0.077934 
1075 TGFb1 CDYL12 -0.099515 1120 GNAS2 CSPG 0.077801 
1076 ICAM1 TGFb1 -0.099432 1121 GCA NOS3 0.077197 
1077 GDI2 BTF3 -0.098632 1122 GCA c-Jun -0.077142 
1078 Endothelin1 CFH -0.09834 1123 NOS3 ICAM1 0.077071 
1079 PHGDH GNAS2 0.098245 1124 UGDH TOR3A 0.076896 
1080 ICAM1 CALM2 -0.098076 1125 GNAS2 CXCL12 -0.076881 
1081 SMAD3 GNAS2 -0.097178 1126 SMAD3 TGFb1 0.076864 
1082 GCA RAMP3 0.096418 1127 PRSS23 CASP3 0.076568 
1083 RAMP3 GCA -0.095663 1128 PRSS23 c-Jun 0.075995 
1084 CSPG PHGDH -0.095599 1129 AQP1 TOR3A -0.075687 
1085 SMAD3 CDYL12 -0.09506 1130 PLD ATP6V0D1 0.07524 
1086 RAMP3 GDI2 0.095051 1131 CSPG BTF3 -0.074958 
1087 CDYL12 GDI2 0.093695 1132 Endothelin1 FGF1 0.074869 
1088 GCA TGFb-R2 -0.093554 1133 CFH PLD 0.074743 
1089 AQP1 FZD4 0.092528 1134 CXCL12 UGDH 0.073585 
1090 NOS3 GTPBP4 -0.092357 1135 RAMP3 ICAM1 -0.073403 
1091 RHOJ ATP6V0D1 0.091783 1136 UGDH FZD4 0.072966 
1092 FGF1 RPIB9 0.091172 1137 SMAD3 GTPBP4 -0.072951 
1093 RPIB9 GNAS2 0.090822 1138 RAMP3 SMAD2 -0.072731 
1094 FGF1 AQP1 0.090385 1139 CXCL12 PLD 0.072361 
1095 SMAD2 PRSS23 -0.090107 1140 SMAD2 TOR3A 0.07211 
1096 ATP6V0D1 GDI2 0.089239 1141 CSPG HOXA3 0.071653 
1097 SMAD2 GNAS2 0.08878 1142 GNAS2 TGFb-R2 0.071475 
1098 RHOJ TOR3A -0.088269 1143 PRSS23 GTPBP4 0.070735 
1099 ICAM1 GNAS2 0.086516 1144 RHOJ GTPBP4 -0.070687 
1100 FZD4 NOS3 0.086504 1145 UGDH PHGDH -0.07038 
1101 ATP6V0D1 CASP3 -0.085988 1146 CDYL12 TGFb-R2 -0.070223 
1102 RHOJ TGFb1 -0.08597 1147 CFH TOR3A -0.069621 
1103 SMAD3 TOR3A -0.085956 1148 HOXA3 Endothelin1 0.069464 
1104 PHGDH GTPBP4 0.085801 1149 FZD4 ATP6V0D1 0.069382 
1105 FGF1 CYR61 0.085685 1150 FGF1 ATP6V0D1 0.069161 
1106 FGF1 FZD4 0.085373 1151 Endothelin1 ATP6V0D1 0.06901 
1107 CFH SMAD2 -0.085103 1152 TOR3A ATP6V0D1 0.068918 
1108 KLF6 GTPBP4 -0.0846 1153 RAMP3 GNAS2 -0.068126 
1109 RPIB9 c-Jun -0.083738 1154 AQP1 HOXA3 0.068006 
1110 SMAD2 GAPDH -0.083507 1155 CYR61 TOR3A 0.067978 
1111 CYR61 CDYL12 0.083023 1156 CXCL12 PRSS23 -0.067909 
1112 GNAS2 CASP3 -0.082553 1157 RAMP3 TGFb1 -0.067827 
1113 TOR3A CYR61 0.082552 1158 NOS3 GDI2 0.067631 
1114 AQP1 GCA 0.081266 1159 GCA CFH 0.06698 
1115 FGF1 RHOJ 0.08113 1160 NOS3 TGFb-R2 -0.06661 
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1161 FGF1 RAMP3 -0.06658 1206 PRSS23 ATP6V0D1 0.053409
1162 RAMP3 c-Jun 0.066469 1207 FGF1 BTF3 -0.052939
1163 CXCL12 SMAD3 0.066343 1208 ICAM1 NOS3 -0.052836
1164 HOXA3 GCA 0.066035 1209 CXCL12 TOR3A 0.052434
1165 CFL1 PHGDH -0.065913 1210 HOXA3 CFH 0.052311
1166 CFH ATP6V0D1 0.065912 1211 SMAD3 UGDH 0.052293
1167 UGDH BTF3 0.065391 1212 CDYL12 RAMP3 -0.051987
1168 PRG GDI2 -0.065074 1213 GAPDH GAPDH 0.050888
1169 CYR61 HOXA3 -0.064949 1214 PRSS23 TGFb-R2 0.050703
1170 RAMP3 PLD 0.064598 1215 NOS3 SMAD2 -0.049944
1171 AQP1 NOS3 0.064439 1216 SMAD2 NOS3 0.049899
1172 c-Jun AQP1 -0.064146 1217 CXCL12 FZD4 0.049283
1173 CSPG PRG 0.064071 1218 SMAD3 GDI2 0.048709
1174 UGDH RAMP3 0.064014 1219 CSPG RHOJ 0.048541
1175 RAMP3 TGFb-R2 -0.063445 1220 GDI2 Endothelin1 0.048475
1176 GAPDH ATP6V0D1 0.062921 1221 c-Jun TGFb-R2 -0.048419
1177 CFH CDYL12 0.062279 1222 TOR3A GTPBP4 -0.04841
1178 CASP3 TOR3A 0.062116 1223 CSPG CFH 0.048031
1179 HOXA3 ATP6V0D1 0.061754 1224 TGFb1 AQP1 -0.04787
1180 RPIB9 GTPBP4 -0.061006 1225 GDI2 TGFb-R2 0.047316
1181 PRG CASP3 0.060645 1226 FGF1 CXCL12 0.047263
1182 NOS3 PLD 0.060515 1227 CSPG CASP3 0.046823
1183 GCA CYR61 -0.060192 1228 SMAD2 GTPBP4 -0.046543
1184 GDI2 FGF1 0.059297 1229 FGF1 ICAM1 0.046307
1185 TGFb-R2 CDYL12 0.059089 1230 NOS3 GNAS2 0.046218
1186 TGFb-R2 TOR3A 0.058657 1231 TGFb-R2 GTPBP4 -0.046167
1187 FGF1 PHGDH -0.058264 1232 GAPDH RPIB9 -0.045898
1188 GAPDH TGFb-R2 0.057832 1233 UGDH PRSS23 -0.04542
1189 KLF6 SMAD3 0.057792 1234 SMAD3 Endothelin1 -0.045374
1190 HOXA3 ICAM1 -0.057733 1235 CXCL12 c-Jun 0.044251
1191 GCA ATP6V0D1 0.057357 1236 GDI2 CDYL12 -0.043086
1192 RAMP3 CDYL12 -0.057261 1237 GNAS2 ATP6V0D1 -0.043007
1193 CSPG SMAD3 0.057168 1238 HOXA3 GTPBP4 -0.042365
1194 FZD4 GTPBP4 -0.057107 1239 TGFb-R2 RAMP3 -0.042349
1195 TOR3A RAMP3 0.056591 1240 UGDH GCA -0.042267
1196 RPIB9 FZD4 0.055868 1241 NOS3 CFL1 0.041936
1197 ICAM1 AQP1 -0.055842 1242 GTPBP4 SMAD2 -0.041879
1198 FGF1 NOS3 0.055732 1243 CXCL12 HOXA3 0.041873
1199 RPIB9 TGFb-R2 -0.054799 1244 CSPG GDI2 0.041696
1200 FGF1 TOR3A 0.054268 1245 GNAS2 GTPBP4 0.040727
1201 RAMP3 FZD4 0.054218 1246 GDI2 ICAM1 0.040684
1202 NOS3 TOR3A -0.054059 1247 GCA FZD4 0.040527
1203 FZD4 CYR61 -0.05394 1248 GCA UGDH 0.040334
1204 FZD4 TOR3A -0.05375 1249 CXCL12 BTF3 0.040212
1205 AQP1 PHGDH -0.053721 1250 PRSS23 ICAM1 -0.039704
 92
Position from to Strength of interaction Position from to 
Strength of 
interaction 
1251 HOXA3 GDI2 -0.039585 1296 CSPG RPIB9 -0.021518 
1252 RAMP3 GTPBP4 -0.03857 1297 CFH ICAM1 0.021479 
1253 TGFb1 UGDH -0.038122 1298 ICAM1 SMAD2 0.020781 
1254 GCA GNAS2 -0.037891 1299 CSPG GTPBP4 -0.020641 
1255 TGFb1 SMAD3 -0.037211 1300 GTPBP4 AQP1 -0.019944 
1256 RAMP3 FGF1 -0.036553 1301 CSPG GNAS2 -0.019624 
1257 Endothelin1 GNAS2 -0.036484 1302 SMAD3 SMAD2 -0.019514 
1258 SMAD2 TGFb1 0.03644 1303 CXCL12 CFH -0.019394 
1259 FGF1 GNAS2 0.036397 1304 RAMP3 ATP6V0D1 0.019166 
1260 CSPG KLF6 -0.036301 1305 GAPDH CDYL12 -0.018925 
1261 PHGDH CASP3 -0.036258 1306 PRSS23 FZD4 0.018764 
1262 FGF1 TGFb1 0.035926 1307 RHOJ RAMP3 0.018729 
1263 CFH GTPBP4 -0.035682 1308 CALM2 CDYL12 0.018216 
1264 SMAD3 ATP6V0D1 0.035381 1309 CSPG Endothelin1 0.0181 
1265 SMAD2 ICAM1 0.034694 1310 CSPG CYR61 0.017712 
1266 KLF6 TGFb1 0.033117 1311 ICAM1 GAPDH -0.017039 
1267 GTPBP4 SMAD3 -0.032841 1312 GCA Endothelin1 0.016283 
1268 TGFb1 GNAS2 -0.032829 1313 c-Jun GTPBP4 -0.016115 
1269 c-Jun ATP6V0D1 0.032591 1314 UGDH TGFb-R2 0.015939 
1270 CDYL12 CFH 0.032497 1315 CYR61 GTPBP4 -0.015793 
1271 TGFb1 FZD4 -0.032205 1316 HOXA3 PRG -0.015214 
1272 AQP1 CDYL12 0.031851 1317 FGF1 TGFb-R2 -0.014054 
1273 Endothelin1 GTPBP4 -0.031419 1318 CSPG TGFb-R2 -0.013688 
1274 CSPG CDYL12 -0.030937 1319 CSPG ICAM1 0.013586 
1275 CXCL12 PRG -0.030393 1320 GTPBP4 GNAS2 -0.012982 
1276 GDI2 ATP6V0D1 0.030233 1321 PHGDH GAPDH -0.012926 
1277 CXCL12 GTPBP4 0.029552 1322 GNAS2 RHOJ -0.012764 
1278 RAMP3 Endothelin1 0.0293 1323 FGF1 CALM2 0.012379 
1279 CXCL12 NOS3 -0.02826 1324 AQP1 GTPBP4 -0.011851 
1280 HOXA3 TGFb-R2 0.0281 1325 NOS3 HOXA3 -0.011407 
1281 TGFb1 NOS3 0.028084 1326 PHGDH SMAD3 -0.011334 
1282 GDI2 GNAS2 0.027886 1327 GDI2 GTPBP4 -0.011329 
1283 GAPDH GTPBP4 0.027262 1328 RAMP3 TOR3A 0.011063 
1284 TGFb1 CASP3 0.026022 1329 SMAD2 ATP6V0D1 0.010975 
1285 GTPBP4 UGDH -0.025925 1330 FGF1 UGDH -0.010446 
1286 RAMP3 NOS3 0.025804 1331 GCA GTPBP4 -0.010385 
1287 CXCL12 GNAS2 0.025759 1332 RAMP3 KLF6 -0.010189 
1288 PHGDH SMAD2 -0.02565 1333 SMAD2 TGFb-R2 -0.010061 
1289 AQP1 CALM2 0.025582 1334 CFH KLF6 -0.009063 
1290 UGDH ATP6V0D1 0.02521 1335 HOXA3 GNAS2 -0.008812 
1291 NOS3 ATP6V0D1 0.025143 1336 FGF1 GAPDH -0.00809 
1292 TGFb-R2 SMAD3 0.024022 1337 GCA TGFb1 0.00773 
1293 CSPG PLD 0.023137 1338 AQP1 ATP6V0D1 -0.007463 
1294 AQP1 GDI2 -0.023122 1339 GAPDH SMAD2 -0.007294 
1295 CSPG UGDH 0.022083 1340 c-Jun SMAD2 -0.007251 
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1341 CSPG c-Jun 0.007172 1356 CSPG NOS3 0.003981
1342 FGF1 Endothelin1 0.006814 1357 GAPDH GDI2 -0.003754
1343 FGF1 c-Jun -0.006599 1358 FGF1 GTPBP4 0.003615
1344 RAMP3 CYR61 0.006419 1359 HOXA3 CALM2 -0.003165
1345 UGDH c-Jun -0.006185 1360 CSPG FZD4 -0.003139
1346 TGFb1 GTPBP4 -0.005989 1361 GCA TOR3A -0.002917
1347 CSPG TOR3A -0.005917 1362 ICAM1 GTPBP4 0.002773
1348 Endothelin1 ICAM1 0.005312 1363 CSPG ATP6V0D1 -0.002376
1349 CYR61 CYR61 -0.005309 1364 AQP1 GNAS2 -0.002362
1350 AQP1 TGFb1 -0.005141 1365 GDI2 SMAD2 0.00147
1351 UGDH GTPBP4 -0.004599 1366 c-Jun NOS3 -0.001442
1352 CFL1 GTPBP4 0.004236 1367 CFH RAMP3 -0.000653
1353 CSPG SMAD2 -0.004167 1368 CSPG RAMP3 -0.000426
1354 CSPG TGFb1 0.004105 1369 AQP1 RHOJ -0.000233
1355 FGF1 CFH 0.004089  
Interactions between transiently expressed candidate genes were ranked according to their 
strength, starting from the strongest value of interaction. Certain threshold values for both, 
activating and inhibitory effects were set in order to incorporate only the most significant 
interactions into the gene network relevant to diabetic microangiopathy. Positive values 
representing activating effects had to be greater than a certain threshold of 1.334 , whereas 
negative values indicating inhibitory effects had to be smaller than -1.130. Three interactions 
involving HOXA3 were found to be significant for the gene network of relevance for diabetic 
microangiopathy. These were the activating and the inhibitory effect of CFL1 and CASP3 
respectively on HOXA3 as well as a positive effect of HOXA3 on its own expression.  
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Abbreviations 
 
7-AAD  …7-amino-actinomycin D 
80K-H   …80 kDa protein substrate for protein kinase C 
ABL   …Abelson tyrosine kinase 
ADF   …Actin depolymerising factor 
AGE   …Advanced glycation end product 
ATPase  …Adenosine triphosphatase 
ATP6VOD1  …D1 subunit of the transmembrane VO domain of ATPase 
BCR   …B cell receptor 
BECs   …Blood vessel endothelial cells 
BSA   …Bovine serum albumin 
CASP3  …Caspase 3 
cDNA   …Complementary deoxyribonucleic acid 
CFL1   …Cofilin1 
CMV   …Cytomegalovirus 
C1s   …serine protease (subunit of the multimeric C1 protein complex) 
Ct   …Cycle threshold  
CXCL12  …Chemokine (C-X-C motif) ligand 12 
CXCR4  …Chemokine (C-X-C motif) receptor 4  
DAG   …Diacylglycerol 
DAPI   ...4´6-diamidino-2-phenylindole dihydrochloride 
DKA   …Diabetic ketoacidosis 
DMA   …Diabetic microangiopathy 
DNA   …Deoxyribonucleic acid 
dNTP   …Deoxynucleotide triphosphate 
ddNTP  …Dideoxynucleotide triphosphate 
EBF   …Early B-cell factor 
ECL   …Enhanced chemiluminescence 
ECM   …Extracellular matrix 
ECMV  …Encephalomyocarditis virus 
EGFP   …Enhanced green fluorescent protein 
eNOS   …Endothelial nitric oxide synthase  
EPHA4  …Ephrin type A receptor 4 
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ET-1   …Endothelin-1 
FBXO   …F-box proteins 
FBS   …Fetal bovine serum 
FC   …Fold change 
FZD4   …Frizzled homolog 4 
GAD   …Glutamic acid decarboxylase 
GAPDH  …Glyceraldehyde-3-phosphate dehydrogenase 
GCA   …Grancalcin 
GFAT   …Glutamine:fructose-6-phosphate amidotransferase 
GDM   …Gestational diabetes mellitus 
GJA1   …Gap junction protein alpha 1 
GSH   …Reduced glutathione 
HMEC-1  …Human microvascular endothelial cell line-1 
HOX genes  …Homeobox genes 
HOXA3  …Homeobox A3 
HOXD3  …Homeobox D3 
hTERT  …Human telomerase reverse transcriptase 
ICAM1  …Intercellular adhesion molecule 1 
iHUVECs  …Immortalized human umbilical vein endothelial cells 
IL-1   …Interleukin-1 
IL-8   …Interleukin-8 
IPTG   …Isopropyl-beta-D-thiogalactopyranoside 
IRES   …Internal ribosomal entry site 
IRES2   …Internal ribosomal entry site 2 
ITGA1  …Integrin alpha 1 
KLF6   …Krüppel-like factor 6 
LacZ   …Beta galactosidase 
LB   …Luria Broth 
MHC class II  …Major histocompatibility complex class II 
MMP-14  …Matrix metalloproteinase-14 
mRNA  …Messenger ribonucleic acid 
NADP+/NADPH …Nicotinamide adenine dinucleotide phosphate  
NARS   …Asparaginyl-tRNA synthetase 
NF-κB   …Nuclear factor-kappa B 
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NOS3   …Nitric oxide synthase 3 
OGT   …O-linked N-acetylglucosamine transferase 
OptiMEM  ...Optimized minimal essential medium 
OST-48  …Oligosaccharyltransferase 48kD subunit 
PAI-1   …Plasminogen activator inhibitor-1 
PARK7  …Parkinson disease 7 
PARP   …Poly (adenosine diphosphate-ribose) polymerase 
PAX1   …Paired box gene 1 
PBGD   …Porphobilinogen desaminase 
PBS   …Phosphate buffered saline 
PCR   …Polymerase chain reaction 
PFA   …Para-formaldehyde 
PHGDH  …3-phosphoglycerate dehydrogenase 
PKC   …Protein kinase C 
PLD   …Phospholipase D 
PRSS23  …Protease serine 23 
p21Ras   …21 kDa protein encoded by the ras gene family 
RAGE   …Receptor of advanced glycation end products 
RHOJ   …Ras homolog gene family member J 
RNA   …Ribonucleic acid 
ROS   …Reactive oxygen species 
RPIB1   …Ribose-5-phosphate isomerase 1 
RPMI   …Roswell Park Memorial Institute (development of RPMI medium) 
SDS   …Sequence detection software 
SDS-PAGE  …Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SERPINE1  …Serpin peptidase inhibitor, clade E, member 1 
SMAD3  …Mothers against decapentaplegic homolog 3 
SMAD4  …Mothers against decapentaplegic homolog 4 
SORBS1  …Sorbin and SH3-domain-containing-1 
TARDBP  …TAR DNA binding protein 
TBS   …Tris-buffered saline 
TBST   …Tris-buffered saline Tween 
TCA   …Trichlor acetic acid 
TCA-cycle  …Tricarboxylic acid cycle 
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TNF-α   …Tumor necrosis factor-alpha 
TGF-β   …Transforming growth factor-beta 
UDP   …Uridine diphosphate 
UGDH  …Uridine diphosphate -glucose dehydrogenase 
UDPGlcNAc  …Uridine diphosphate -N-acetylglucosamine 
uPA   …Urokinase-type plasminogen activator 
uPAR   …Urokinase-type plasminogen activator receptor 
VCAM-1  …Vascular cell adhesion molecule-1 
VEGF   …Vascular endothelial growth factor  
X-gal   …5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
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